ZA200205956B - Xylanase variants having altered sensitivity to xylanase inhibitors. - Google Patents
Xylanase variants having altered sensitivity to xylanase inhibitors. Download PDFInfo
- Publication number
- ZA200205956B ZA200205956B ZA200205956A ZA200205956A ZA200205956B ZA 200205956 B ZA200205956 B ZA 200205956B ZA 200205956 A ZA200205956 A ZA 200205956A ZA 200205956 A ZA200205956 A ZA 200205956A ZA 200205956 B ZA200205956 B ZA 200205956B
- Authority
- ZA
- South Africa
- Prior art keywords
- xylanase
- amino acid
- inhibitor
- polypeptide
- modifications
- Prior art date
Links
- 101710121765 Endo-1,4-beta-xylanase Proteins 0.000 title claims description 327
- 239000003112 inhibitor Substances 0.000 title claims description 141
- 230000035945 sensitivity Effects 0.000 title claims description 28
- 229920001184 polypeptide Polymers 0.000 claims description 112
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 112
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 112
- 102000004190 Enzymes Human genes 0.000 claims description 65
- 108090000790 Enzymes Proteins 0.000 claims description 65
- 238000000034 method Methods 0.000 claims description 55
- 238000012986 modification Methods 0.000 claims description 55
- 230000004048 modification Effects 0.000 claims description 55
- 150000001413 amino acids Chemical class 0.000 claims description 50
- 230000000694 effects Effects 0.000 claims description 46
- 235000014469 Bacillus subtilis Nutrition 0.000 claims description 44
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 29
- 125000000539 amino acid group Chemical group 0.000 claims description 21
- 235000013339 cereals Nutrition 0.000 claims description 20
- 239000000463 material Substances 0.000 claims description 20
- 125000003729 nucleotide group Chemical group 0.000 claims description 20
- 239000002773 nucleotide Substances 0.000 claims description 19
- 239000012634 fragment Substances 0.000 claims description 18
- 238000012545 processing Methods 0.000 claims description 18
- 238000004519 manufacturing process Methods 0.000 claims description 17
- 229920002472 Starch Polymers 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 12
- 235000019698 starch Nutrition 0.000 claims description 12
- 239000008107 starch Substances 0.000 claims description 12
- 238000002741 site-directed mutagenesis Methods 0.000 claims description 10
- -1 N17Y Proteins 0.000 claims description 7
- 229920001131 Pulp (paper) Polymers 0.000 claims description 6
- 230000002829 reductive effect Effects 0.000 claims description 6
- 102200111133 rs387907305 Human genes 0.000 claims description 6
- 102200127696 rs869025583 Human genes 0.000 claims description 6
- 210000002421 cell wall Anatomy 0.000 claims description 5
- 101100218695 Bacillus subtilis (strain 168) bglH gene Proteins 0.000 claims description 4
- 101100545099 Bacillus subtilis (strain 168) yxiH gene Proteins 0.000 claims description 4
- 102220504838 Choline transporter-like protein 4_N29D_mutation Human genes 0.000 claims description 4
- 102220534224 Fibronectin type-III domain-containing protein 3A_Y113D_mutation Human genes 0.000 claims description 4
- 102220468966 Protein TEX261_N17D_mutation Human genes 0.000 claims description 4
- 102220589038 Vacuole membrane protein 1_G34F_mutation Human genes 0.000 claims description 4
- 102200006538 rs121913530 Human genes 0.000 claims description 4
- 102220102504 rs878854150 Human genes 0.000 claims description 4
- 238000004061 bleaching Methods 0.000 claims description 2
- 230000002708 enhancing effect Effects 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 239000002023 wood Substances 0.000 claims description 2
- 102220467117 Runt-related transcription factor 2_Y113A_mutation Human genes 0.000 claims 3
- 102220559236 Voltage-dependent L-type calcium channel subunit alpha-1C_N32K_mutation Human genes 0.000 claims 3
- 102220346421 c.92C>A Human genes 0.000 claims 3
- 102220530637 Putative apolipoprotein(a)-like protein 2_G12F_mutation Human genes 0.000 claims 2
- 230000000593 degrading effect Effects 0.000 claims 1
- 229940088598 enzyme Drugs 0.000 description 62
- 210000004027 cell Anatomy 0.000 description 61
- 241000196324 Embryophyta Species 0.000 description 54
- 235000013312 flour Nutrition 0.000 description 47
- 108090000623 proteins and genes Proteins 0.000 description 41
- 230000014509 gene expression Effects 0.000 description 40
- 239000013598 vector Substances 0.000 description 30
- 235000013305 food Nutrition 0.000 description 29
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 24
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 24
- 241000209140 Triticum Species 0.000 description 24
- 235000021307 Triticum Nutrition 0.000 description 24
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 21
- 102000004169 proteins and genes Human genes 0.000 description 21
- UGXQOOQUZRUVSS-ZZXKWVIFSA-N [5-[3,5-dihydroxy-2-(1,3,4-trihydroxy-5-oxopentan-2-yl)oxyoxan-4-yl]oxy-3,4-dihydroxyoxolan-2-yl]methyl (e)-3-(4-hydroxyphenyl)prop-2-enoate Chemical compound OC1C(OC(CO)C(O)C(O)C=O)OCC(O)C1OC1C(O)C(O)C(COC(=O)\C=C\C=2C=CC(O)=CC=2)O1 UGXQOOQUZRUVSS-ZZXKWVIFSA-N 0.000 description 19
- 229920000617 arabinoxylan Polymers 0.000 description 19
- 108091033319 polynucleotide Proteins 0.000 description 19
- 102000040430 polynucleotide Human genes 0.000 description 19
- 239000002157 polynucleotide Substances 0.000 description 19
- 235000018102 proteins Nutrition 0.000 description 19
- 244000063299 Bacillus subtilis Species 0.000 description 18
- 239000006052 feed supplement Substances 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
- 108010001817 Endo-1,4-beta Xylanases Proteins 0.000 description 17
- 230000035772 mutation Effects 0.000 description 15
- 238000002360 preparation method Methods 0.000 description 15
- 238000003556 assay Methods 0.000 description 14
- 150000007523 nucleic acids Chemical class 0.000 description 12
- 238000006467 substitution reaction Methods 0.000 description 12
- 230000002538 fungal effect Effects 0.000 description 11
- 102000039446 nucleic acids Human genes 0.000 description 11
- 108020004707 nucleic acids Proteins 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 108020004414 DNA Proteins 0.000 description 10
- 241000588724 Escherichia coli Species 0.000 description 10
- 239000000758 substrate Substances 0.000 description 10
- 108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 description 9
- 230000005764 inhibitory process Effects 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- 230000001105 regulatory effect Effects 0.000 description 9
- 230000028327 secretion Effects 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 8
- 235000008429 bread Nutrition 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 230000009466 transformation Effects 0.000 description 8
- 230000009261 transgenic effect Effects 0.000 description 8
- 241000193830 Bacillus <bacterium> Species 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 7
- 230000003993 interaction Effects 0.000 description 7
- 239000002002 slurry Substances 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 241000233866 Fungi Species 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 240000008042 Zea mays Species 0.000 description 6
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 6
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 238000000855 fermentation Methods 0.000 description 6
- 230000004151 fermentation Effects 0.000 description 6
- 238000005194 fractionation Methods 0.000 description 6
- 235000009973 maize Nutrition 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 238000003752 polymerase chain reaction Methods 0.000 description 6
- 238000011002 quantification Methods 0.000 description 6
- 108091026890 Coding region Proteins 0.000 description 5
- 241000235070 Saccharomyces Species 0.000 description 5
- 101000770834 Thermomyces lanuginosus Endo-1,4-beta-xylanase Proteins 0.000 description 5
- 241000499912 Trichoderma reesei Species 0.000 description 5
- 239000007983 Tris buffer Substances 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 230000000875 corresponding effect Effects 0.000 description 5
- 238000012258 culturing Methods 0.000 description 5
- 230000002068 genetic effect Effects 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 230000008929 regeneration Effects 0.000 description 5
- 238000011069 regeneration method Methods 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 230000001131 transforming effect Effects 0.000 description 5
- 210000005253 yeast cell Anatomy 0.000 description 5
- 239000004382 Amylase Substances 0.000 description 4
- 241000228212 Aspergillus Species 0.000 description 4
- 241000228245 Aspergillus niger Species 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 108020001507 fusion proteins Proteins 0.000 description 4
- 102000037865 fusion proteins Human genes 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 229920001221 xylan Polymers 0.000 description 4
- 150000004823 xylans Chemical class 0.000 description 4
- 108010068370 Glutens Proteins 0.000 description 3
- 240000005979 Hordeum vulgare Species 0.000 description 3
- 235000007340 Hordeum vulgare Nutrition 0.000 description 3
- 241000235649 Kluyveromyces Species 0.000 description 3
- 241000209510 Liliopsida Species 0.000 description 3
- 108010076504 Protein Sorting Signals Proteins 0.000 description 3
- 241000187747 Streptomyces Species 0.000 description 3
- 241000187398 Streptomyces lividans Species 0.000 description 3
- 230000001133 acceleration Effects 0.000 description 3
- 230000003197 catalytic effect Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 235000021312 gluten Nutrition 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 238000002703 mutagenesis Methods 0.000 description 3
- 231100000350 mutagenesis Toxicity 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000005507 spraying Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 125000000969 xylosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)CO1)* 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 108010011619 6-Phytase Proteins 0.000 description 2
- 241000589158 Agrobacterium Species 0.000 description 2
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 2
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 108010065511 Amylases Proteins 0.000 description 2
- 102000013142 Amylases Human genes 0.000 description 2
- 241000122821 Aspergillus kawachii Species 0.000 description 2
- 241000228232 Aspergillus tubingensis Species 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 235000007319 Avena orientalis Nutrition 0.000 description 2
- 244000075850 Avena orientalis Species 0.000 description 2
- 241000193752 Bacillus circulans Species 0.000 description 2
- 102100032487 Beta-mannosidase Human genes 0.000 description 2
- 101800000778 Cytochrome b-c1 complex subunit 9 Proteins 0.000 description 2
- 102400000011 Cytochrome b-c1 complex subunit 9 Human genes 0.000 description 2
- 101150108358 GLAA gene Proteins 0.000 description 2
- 102000004157 Hydrolases Human genes 0.000 description 2
- 108090000604 Hydrolases Proteins 0.000 description 2
- 206010020649 Hyperkeratosis Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 244000043158 Lens esculenta Species 0.000 description 2
- 241000218922 Magnoliophyta Species 0.000 description 2
- 244000061176 Nicotiana tabacum Species 0.000 description 2
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 2
- 240000004713 Pisum sativum Species 0.000 description 2
- 235000010582 Pisum sativum Nutrition 0.000 description 2
- 241000589516 Pseudomonas Species 0.000 description 2
- 235000007238 Secale cereale Nutrition 0.000 description 2
- 244000082988 Secale cereale Species 0.000 description 2
- 241000203780 Thermobifida fusca Species 0.000 description 2
- 241000223257 Thermomyces Species 0.000 description 2
- 241000223258 Thermomyces lanuginosus Species 0.000 description 2
- 241000223261 Trichoderma viride Species 0.000 description 2
- 102000005924 Triose-Phosphate Isomerase Human genes 0.000 description 2
- 108700015934 Triose-phosphate isomerases Proteins 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 241000193445 [Clostridium] stercorarium Species 0.000 description 2
- 108010048241 acetamidase Proteins 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical group C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
- 235000019418 amylase Nutrition 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 235000015173 baked goods and baking mixes Nutrition 0.000 description 2
- 108010055059 beta-Mannosidase Proteins 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 241001233957 eudicotyledons Species 0.000 description 2
- 125000003147 glycosyl group Chemical group 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 229940085127 phytase Drugs 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 210000001938 protoplast Anatomy 0.000 description 2
- 238000002708 random mutagenesis Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000001172 regenerating effect Effects 0.000 description 2
- 238000002390 rotary evaporation Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000011869 shoot development Effects 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 238000001238 wet grinding Methods 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- PAWQVTBBRAZDMG-UHFFFAOYSA-N 2-(3-bromo-2-fluorophenyl)acetic acid Chemical compound OC(=O)CC1=CC=CC(Br)=C1F PAWQVTBBRAZDMG-UHFFFAOYSA-N 0.000 description 1
- QRBLKGHRWFGINE-UGWAGOLRSA-N 2-[2-[2-[[2-[[4-[[2-[[6-amino-2-[3-amino-1-[(2,3-diamino-3-oxopropyl)amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[(2r,3s,4s,5s,6s)-3-[(2s,3r,4r,5s)-4-carbamoyl-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)- Chemical compound N=1C(C=2SC=C(N=2)C(N)=O)CSC=1CCNC(=O)C(C(C)=O)NC(=O)C(C)C(O)C(C)NC(=O)C(C(O[C@H]1[C@@]([C@@H](O)[C@H](O)[C@H](CO)O1)(C)O[C@H]1[C@@H]([C@](O)([C@@H](O)C(CO)O1)C(N)=O)O)C=1NC=NC=1)NC(=O)C1=NC(C(CC(N)=O)NCC(N)C(N)=O)=NC(N)=C1C QRBLKGHRWFGINE-UGWAGOLRSA-N 0.000 description 1
- OSJPPGNTCRNQQC-UWTATZPHSA-N 3-phospho-D-glyceric acid Chemical compound OC(=O)[C@H](O)COP(O)(O)=O OSJPPGNTCRNQQC-UWTATZPHSA-N 0.000 description 1
- 241000589156 Agrobacterium rhizogenes Species 0.000 description 1
- 241000589155 Agrobacterium tumefaciens Species 0.000 description 1
- 241000219194 Arabidopsis Species 0.000 description 1
- 241001513093 Aspergillus awamori Species 0.000 description 1
- 241000351920 Aspergillus nidulans Species 0.000 description 1
- 101000666778 Aspergillus niger Endo-1,4-beta-xylanase A Proteins 0.000 description 1
- 101000756530 Aspergillus niger Endo-1,4-beta-xylanase B Proteins 0.000 description 1
- 240000006439 Aspergillus oryzae Species 0.000 description 1
- 235000002247 Aspergillus oryzae Nutrition 0.000 description 1
- 241000193744 Bacillus amyloliquefaciens Species 0.000 description 1
- 241000194108 Bacillus licheniformis Species 0.000 description 1
- 241000194103 Bacillus pumilus Species 0.000 description 1
- 241000486634 Bena Species 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 240000002791 Brassica napus Species 0.000 description 1
- 235000011293 Brassica napus Nutrition 0.000 description 1
- 244000180419 Brassica nigra Species 0.000 description 1
- 235000011291 Brassica nigra Nutrition 0.000 description 1
- 235000011299 Brassica oleracea var botrytis Nutrition 0.000 description 1
- 240000003259 Brassica oleracea var. botrytis Species 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 108010084185 Cellulases Proteins 0.000 description 1
- 102000005575 Cellulases Human genes 0.000 description 1
- 241000186320 Cellulomonas fimi Species 0.000 description 1
- 241000193401 Clostridium acetobutylicum Species 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- 241000218631 Coniferophyta Species 0.000 description 1
- 101150013440 DI19-1 gene Proteins 0.000 description 1
- 229920004518 DION® Polymers 0.000 description 1
- 240000007175 Datura inoxia Species 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 101710132690 Endo-1,4-beta-xylanase A Proteins 0.000 description 1
- 101000896135 Enterobacteria phage T4 Baseplate tail-tube junction protein gp48 Proteins 0.000 description 1
- 101000896134 Escherichia phage Mu Baseplate protein gp48 Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 108091029865 Exogenous DNA Proteins 0.000 description 1
- 101710089384 Extracellular protease Proteins 0.000 description 1
- 108050001049 Extracellular proteins Proteins 0.000 description 1
- 241000605896 Fibrobacter succinogenes Species 0.000 description 1
- 108700005088 Fungal Genes Proteins 0.000 description 1
- 108010093031 Galactosidases Proteins 0.000 description 1
- 102000002464 Galactosidases Human genes 0.000 description 1
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 1
- 102100022624 Glucoamylase Human genes 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 101150069554 HIS4 gene Proteins 0.000 description 1
- 229920002488 Hemicellulose Polymers 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 241001138401 Kluyveromyces lactis Species 0.000 description 1
- 108010059881 Lactase Proteins 0.000 description 1
- 235000014647 Lens culinaris subsp culinaris Nutrition 0.000 description 1
- 235000010666 Lens esculenta Nutrition 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000233894 Neocallimastix patriciarum Species 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 241000208133 Nicotiana plumbaginifolia Species 0.000 description 1
- 241000203619 Nocardiopsis dassonvillei Species 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 102100037214 Orotidine 5'-phosphate decarboxylase Human genes 0.000 description 1
- 108010055012 Orotidine-5'-phosphate decarboxylase Proteins 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- LTQCLFMNABRKSH-UHFFFAOYSA-N Phleomycin Natural products N=1C(C=2SC=C(N=2)C(N)=O)CSC=1CCNC(=O)C(C(O)C)NC(=O)C(C)C(O)C(C)NC(=O)C(C(OC1C(C(O)C(O)C(CO)O1)OC1C(C(OC(N)=O)C(O)C(CO)O1)O)C=1NC=NC=1)NC(=O)C1=NC(C(CC(N)=O)NCC(N)C(N)=O)=NC(N)=C1C LTQCLFMNABRKSH-UHFFFAOYSA-N 0.000 description 1
- 108010035235 Phleomycins Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 108010059820 Polygalacturonase Proteins 0.000 description 1
- 108010039918 Polylysine Chemical group 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 241000192026 Ruminococcus flavefaciens Species 0.000 description 1
- 101150014136 SUC2 gene Proteins 0.000 description 1
- 241000222481 Schizophyllum commune Species 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 240000006394 Sorghum bicolor Species 0.000 description 1
- 235000011684 Sorghum saccharatum Nutrition 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 101000781264 Streptomyces lividans Endo-1,4-beta-xylanase B Proteins 0.000 description 1
- 101000805012 Streptomyces lividans Endo-1,4-beta-xylanase C Proteins 0.000 description 1
- 241000187180 Streptomyces sp. Species 0.000 description 1
- 241000187094 Streptomyces thermoviolaceus Species 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical group OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 241000223259 Trichoderma Species 0.000 description 1
- 241000223260 Trichoderma harzianum Species 0.000 description 1
- 101000847267 Trichoderma harzianum Endo-1,4-beta-xylanase Proteins 0.000 description 1
- 235000019714 Triticale Nutrition 0.000 description 1
- 240000006677 Vicia faba Species 0.000 description 1
- 235000010749 Vicia faba Nutrition 0.000 description 1
- 240000002570 Vicia narbonensis Species 0.000 description 1
- 235000010713 Vicia narbonensis Nutrition 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229940126574 aminoglycoside antibiotic Drugs 0.000 description 1
- 239000002647 aminoglycoside antibiotic agent Substances 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 239000001166 ammonium sulphate Substances 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229940025131 amylases Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- RIOXQFHNBCKOKP-UHFFFAOYSA-N benomyl Chemical compound C1=CC=C2N(C(=O)NCCCC)C(NC(=O)OC)=NC2=C1 RIOXQFHNBCKOKP-UHFFFAOYSA-N 0.000 description 1
- MITFXPHMIHQXPI-UHFFFAOYSA-N benzoxaprofen Natural products N=1C2=CC(C(C(O)=O)C)=CC=C2OC=1C1=CC=C(Cl)C=C1 MITFXPHMIHQXPI-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- GINJFDRNADDBIN-FXQIFTODSA-N bilanafos Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCP(C)(O)=O GINJFDRNADDBIN-FXQIFTODSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 108010089934 carbohydrase Proteins 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 108020001778 catalytic domains Proteins 0.000 description 1
- 238000005277 cation exchange chromatography Methods 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 235000012495 crackers Nutrition 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- PCHPORCSPXIHLZ-UHFFFAOYSA-N diphenhydramine hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C(OCC[NH+](C)C)C1=CC=CC=C1 PCHPORCSPXIHLZ-UHFFFAOYSA-N 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 108010093305 exopolygalacturonase Proteins 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 230000002363 herbicidal effect Effects 0.000 description 1
- 239000004009 herbicide Substances 0.000 description 1
- 108010018734 hexose oxidase Proteins 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 239000000416 hydrocolloid Substances 0.000 description 1
- 230000014726 immortalization of host cell Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 229940116108 lactase Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical compound CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000013379 molasses Nutrition 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 239000003471 mutagenic agent Substances 0.000 description 1
- 231100000707 mutagenic chemical Toxicity 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000001477 organic nitrogen group Chemical group 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920000656 polylysine Chemical group 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 235000012015 potatoes Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 235000012434 pretzels Nutrition 0.000 description 1
- 235000005974 protein supplement Nutrition 0.000 description 1
- 229940116540 protein supplement Drugs 0.000 description 1
- 230000018883 protein targeting Effects 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000001054 red pigment Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 230000021749 root development Effects 0.000 description 1
- 238000009938 salting Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 235000012184 tortilla Nutrition 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 239000010937 tungsten Substances 0.000 description 1
- 101150101900 uidA gene Proteins 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 241000228158 x Triticosecale Species 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Description
ENZYME
Field of the invention : 5
The present invention relates to mutant xylanase enzymes having an altered sensitivity to xylanase inhibitors. The present invention also relates to the use of these mutant enzymes in processing plant materials.
For many years, endo-f3-1,4-xylanases (EC 3.2.1.8) (referred to herein as xylanases) have been used for the modification of complex carbohydrates derived from plant cell wall material. It is well known in the art that the functionality of different xylanases (derived from different micro organisms or plants) differs enormously.
Comprehensive studies characterising the functionality of xylanases have been done on well characterised and pure substrates (Kormelink ef al., 1992). These studies show that different xylanases have different specific requirements with respect to substitution of the xylose backbone of the arabinoxylan (AX). Some xylanases require three un-substituted xylose residues to hydrolyse the xylose backbone; others require only one or two. The reasons for these differences in specificity is thought to be due to the three dimensional structure within the catalytic domains, which in turn is dependent on the primary structure of the xylanase, i.e. the amino acid sequence. However, the translation of these differences in the amino acid sequences into differences in the functionality of the xylanases, has up until now not been documented when the xylanase acts in a complex environment, such as plant material.
The xylanase substrates found in wheat (wheat flour), have traditionally been divided into two fractions: The water un-extractable AX (WU-AX) and the water extractable AX (WE-AX). The WU-AX:WE-AX ratio is approx. 70:30 in wheat flour. There have been numerous explanations as to why there are two different fractions of AX. The older literature (D’Appolonia and MacArthur (1976) and Montgomery and Smith (1955))
describes quite high differences in the substitution degree between WE-AX and WU-AX.
The highest degree of substitution was found in WE-AX. This was used to explain why , some of the AX was extractable. The high degree of substitution made the polymer soluble, compared to a lower substitution degree, which would cause hydrogen bonding . 5 between polymers and consequently precipitation.
The difference between the functionality of different xylanases has been thought to be due to differences in xylanase specificity and thereby their preference for the WU-AX or the
WE-AX substrates.
In some applications (e.g. bakery) it is desirable to produce high molecular weight (HMW) soluble polymers from the WU-AX fraction. Such polymers have been correlated to a volume increase in bread making (Rouau, 1993; Rouau ef al., 1994 and
Courtin et al., 1999).
In other applications it is desirable to modify the HMW WU-AX, making the molecular weight lower, reducing their hydrocolloid effect and hence water-binding in the product (crackers, flour separation, etc.)
These different applications require different functionalities of the xylanases used to do the job. As mentioned above, the difference in functionality has been explained by the different substrate specificities of the xylanases.
By contrast to earlier studies, we have now shown that other factors are more important in determining xylanase functionality than the substrate specificity of the xylanases determined on pure well-characterised substrates. The data presented herein show that endogenous xylanase inhibitors dictate the functionality of the xylanases currently used in, for example, wheat flour systems. This means that a xylanase that normally modifies the
WU-AX, giving increased dough liquid viscosity in a wheat flour system, has a different functionality if the endogenous xylanase inhibitor is absent in the wheat flour. Thus, our findings indicate that the design and application of uninhibited xylanases, for example, using site-directed mutagenesis could be a way to mimic the absence of xylanase inhibitors in various plant materials, giving new xylanases with completely new functionality. Such xylanases would be very effective in applications where a reduction in . 5 viscosity is required. The uninhibited xylanase would act rapidly on the AX, and be primarily influenced by its specific activity, rather than by endogenous inhibitors. From our studies, we consider that the inhibitory effects are likely to be far more important than the specific activity. Indeed our results show for the first time that there are 10 to 50 fold differences in inhibition levels between the family 11 xylanases.
Furthermore, we have gone on to design and test a series of xylanases modified by site- directed mutagenesis to demonstrate that xylanases can be produced that have reduced sensitivity to xylanase inhibitors present in plant materials. In particular, we have identified a number of residues in family 11 xylanases which influence the degree of inhibition of the xylanase.
Thus, it will be possible to produce variant xylanases having reduced sensitivity to xylanase inhibitors and hence altered functionality. This will, for example, allow a reduction in the amount of xylanase required in a number of applications such as animal feed, starch production, bakery, flour separation (wetmilling) and, paper and pulp production.
Accordingly, the present invention provides a variant xylanase polypeptide, or fragment thereof having xylanase activity, comprising one or more amino acid modifications such that the polypeptide or fragment thereof has an altered sensitivity to a xylanase inhibitor as compared with the parent enzyme.
Here, the “parent enzyme” is the xylanase enzyme from which the variant xylanase enzyme is derived or derivable. With respect to the term “derivable”, the variant need not necessarily be derived from the parent enzyme. Instead, the variant could be prepared, for example, by use of recombinant DNA techniques that utilise nucleotide sequence(s) encoding said variant xylanase sequence - i.e. here the nucleotide sequence(s) are similar to mutated nucleotide sequence(s) but they are not prepared by mutation of the parent nucleotide sequence(s). The variant may even be prepared by chemically modifying a ) parent enzyme. ' 5 For some embodiments the parent enzyme is the wild type enzyme. The term “wild type”
Is a term of art understood by skilled persons and includes a phenotype that is characteristic of most of the members of a species occurring naturally and contrasting with the phenotype of a mutant. Thus, in the present context, the wild type enzyme may be a form of the enzyme naturally found in most members of the relevant species.
Generally, the relevant wild type enzyme in relation to the variant polypeptides of the invention is the most closely related corresponding wild type enzyme in terms of sequence homology. For example, for the particular mutant xylanases described in the examples, the corresponding wild type enzyme is the wild type B. subtilis xylanase A, more specifically the wild type B. subtilis xylanase A published by Paice ef al., 1986 and shown as SEQLD. 1. However, where a particular wild type sequence has been used as the basis for producing a variant polypeptide of the invention, this will be the corresponding wild type sequence regardless of the existence of another wild type sequence that is more closely related in terms of amino acid sequence homology.
For some embodiments, preferably the variant polypeptide is derived from a family 11 xylanase.
One of our surprising findings is that in our studies so far a mutation in the xylanase active site has no measurable effect on inhibition against the xylanase inhibitor. This is in direct contrast to the mutation(s) that are made outside of the active site — which mutations are discussed in more detail below.
In a preferred aspect the amino acid modification is of one or more surface amino acid . residues.
In a more preferred aspect the amino acid modification is of one or more solvent accessible residues. Here, the solvent is water.
In a more preferred aspect the amino acid modification is of one or more surface residues outside of the active site. : In a highly preferred aspect the amino acid modification is of one or more surface residues outside of the active site and which is/are at least 8 % solvent accessible. Here, the solvent is water.
In a highly preferred aspect the amino acid modification is of one or more surface residues outside of the active site and which is/are at least 10 % solvent accessible. Here, the solvent is water.
Solvent accessibility can be determined using Swiss-PdbViewer (version 3.5b1), which can be located via the internet at hutp://www.expasy.ch/spdbv/mainpage.html. The Swiss-
PdbViewer is presented by Glaxo Wellcome Experimental Research.
The surface amino acids of xylanase enzymes are determinable by a person skilled in the art.
By way of example, the B. subtilis amino acid sequence for xylanase A is shown as SEQ
I.D. No. 1. With respect to this sequence, the surface amino acid residues are:
Alal-Trp6, Asn8, Thrl0-Gly23, Asn25, Ser27, Asn29, Ser31-Asn32, Gly34,
Thr43-Thr44, Serd6-Thr50, AsnS52, Asn54, Gly56-Asn6l, Asn63, Arg73-Leu7e,
Thr87-Arg89, Thr91-Lys95, Thr97, Lys99, Aspl01-Gly102, Thri104, Thr109-
Thr111, Tyr113-Asnil4, Aspl19-Thrl24, Thr126, Glnl133-Asnl41l, Thrl43,
Thr145, Thr147-Asn148, Asnl51, Lys154-Gly157, Asn159-Leul60, Serl62-
Trpl64, GInl75, Serl177, Ser179, Asn181, Thr183, Trpl8S.
As indicated, the surface amino acids of other xylanase enzymes (such as Thermomyces lanuginosus xylanase A, whose coding nucleotide sequence is presented as SEQ ID No. 9) are determinable by a person skilled in the art.
Hence, for some aspects the present invention encompasses a variant Xylanase : polypeptide, or fragment thereof having xylanase activity, which variant xylanase polypeptide or fragment comprises one or more amino acid modifications at any one of amino acid residues:
Alal-Trp6, Asn8, Thr10-Gly23, Asn25, Ser27, Asn29, Ser31-Asn32, Gly34,
Thr43-Thr44, Ser46-Thr50, AsnS2, AsnS4, Gly56-Asn61, Asn63, Arg73-Leu76,
Thr87-Arg89, Thr91-Lys9S, Thr97, Lys99, Aspl01-Gly102, Thri04, Thr109- .
Thrl1l, Tyrl13-Asnl14, Aspl19-Thri24, Thr126, Glnl33-Asnl4l, Thrl43,
Thr145, Thr147-Asnl48, AsnlS1, Lysl154-Glyl157, Asn159-Leul60, Serl62-
Trpl164, GInl75, Ser177, Serl79, Asn181, Thr183, Trp185 of the B. subtilis amino acid sequence shown as SEQ 1.D. No. 1 or its/their equivalent positions in other homologous xylanase polypeptides.
Thus, in one embodiment, the present invention provides a variant xylanase polypeptide, or fragment thereof having xylanase activity, comprising one or more amino acid modifications at any one of amino acid residues numbers: 11,12, 13,15, 17, 29, 31, 32, 34, 113, 114, 119, 120, 121, 122, 123, 124 and 175 of the B. subtilis amino acid sequence shown as SEQ LD. No. 1 or their equivalent positions in other homologous xylanase polypeptides.
In one embodiment, the present invention provides a variant xylanase polypeptide or fragment thereof having xylanase activity, comprising one or more amino acid modifications at any one of amino acid residues numbers 11, 12 and 13 of the B. subtilis . amino acid sequence shown as SEQ LD. No. 1 or their equivalent positions in other homologous xylanase polypeptides.
Specific preferred examples of modifications made are presented in the Examples section herein.
For some embodiments, preferably the variant xylanase polypeptide, or fragment thereof " 5 having xylanase activity, comprises one or more amino acid modifications at any one of amino acid residues numbers: 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 29, 30, 31, 32, 33, 34, 35, 36, 37, 61, 62, 63, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 173,174, 175, 176, 177, 178 of the B. subtilis amino acid sequence shown as SEQ LD. No. 1 or their equivalent positions in other homologous xylanase polypeptides.
For convenience, we sometimes refer to the amino acid residues numbers: 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 29, 30, 31, 32, 33, 34, 35, 36, 37, 61, 62, 63, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 173, 174, 175, 176, 177, 178 as
BAND IL.
Figure 1 shows the 3-D structure of B. subtilis xylanase having the amino acid sequence shown as SEQ ID. No. 1. BAND 1 is depicted in Figure 1 as the upper layer of the molecule and extends approximately 13 Angstroms from the top of the molecule when the molecule is orientated as shown in Figure 1. BAND 1 ends with the residue Phe 125 on the left hand side when viewing Figure 1 and with the residue Asn 61 on the right hand side when viewing Figure 1.
In addition, or in the alternative, for some embodiments, preferably the variant xylanase polypeptide, or fragment thereof having xylanase activity, comprises one or more amino acid modifications at any one of the other amino acid residues.
Preferably said other modifications may occur at any one or more of amino acid residues ] numbers: 3,4, 5,6, 7,19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 38, 39, 40, 41, 42, 43, 44, 45, 55,56,57,58,59,60, 64, 65, 66,67, 68,69, 70,71,72,73,74, 75,76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 108, 109, 110, 126, 127, 128, 129, 130, 131, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 179, 180,
181, 182, 183 of the B. subtilis amino acid sequence shown as SEQ LD. No. 1 or their equivalent positions in other homologous Xylanase polypeptides.
For convenience, we sometimes refer to the amino acid residues numbers: 3, 4, 5, 6, 7, 19, : 5 20,21, 22,23, 24,25, 26,27, 28, 38, 39, 40, 41, 42, 43, 44, 45, 55, 56, 57, 58, 59, 60, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 108, 109, 110, 126, 127, 128, 129, 130, 131, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 179, 180, 181, 182, 183 of the B. subtilis amino acid sequence shown as BAND 2.
Preferably said other modifications may occur at any one or more of the surface amino acid residues numbers: 3, 4, 5, 6, 19, 20, 21, 22, 23, 25, 27, 43, 44, 56, 57, 58, 59, 60, 73, 74,75,76, 87, 89,91, 92,93, 94, 109, 110, 126, 159, 160, 162, 163, 164, 179, 181, 183 of the B. subtilis amino acid sequence shown as SEQ LD. No. 1 or their equivalent positions in other homologous xylanase polypeptides.
Preferably, the present invention encompasses a variant xylanase polypeptide, or fragment thereof having xylanase activity, which comprises one or more amino acid modifications in BAND 1 and optionally/or BAND 2 of the B. subtilis amino acid sequence or their equivalent positions (bands) in other homologous xylanase polypeptides. Hence, the modification is in at least BAND I; but could be in just BAND 2 alone.
The variant xylanase polypeptide may comprise other modifications in other amino acid residues, such as modification at any one of amino acid residues: 1, 2, 46, 47, 48, 49, 50, 51,52, 53, 54, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 184, 185 of the B. subtilis amino acid sequence shown as SEQ
LD. No. 1 or their equivalent positions in other homologous xylanase polypeptides.
The variant xylanase polypeptide may comprise other modifications in other surface amino acid residues, such as modification at any one of the surface amino acid residues: 1,2, 46, 47, 48, 49, 50, 52, 54, 95, 97, 99, 101, 102, 104, 133, 134, 135, 136, 137, 138,
139, 140, 141, 143, 145, 147, 148, 151, 154, 155, 156, 157, 185 of the B. subtilis amino acid sequence shown as SEQ 1.D. No. 1 or their equivalent positions in other homologous xylanase polypeptides.
Preferably, the inhibitor is an inhibitor found naturally in plant tissues. Preferably the sensitivity of the variant xylanase enzyme to the inhibitor is reduced as compared to the parent xylanase enzyme.
The present invention also provides a nucleic acid molecule (a nucleotide sequence) encoding a polypeptide of the invention. Also provided is a vector comprising a nucleic acid of the invention, optionally operably linked to a regulatory sequence capable of directing expression of said nucleic acid in a suitable host cell. A host cell comprising a nucleic acid or a vector of the invention is also provided.
In another aspect the present invention provides a method of making a polypeptide of the invention comprising transforming a host cell with a nucleic acid encoding said polypeptide, culturing the transformed cell and expressing said polypeptide.
Our results show that these variant polypeptides have improved properties that make them suitable for a variety of applications, such as bakery, animal feed, starch production, flour separation (wetmilling) and, paper and pulp production.
Accordingly, the present invention also provides the use of a variant polypeptide of the invention in a method of modifying plant materials.
Also provided is the use of a variant polypeptide of the invention in baking. The invention further provides the use of a variant polypeptide of the invention in processing cereals, starch production and animal feed and the use of a variant polypeptide of the invention in processing wood, for example in enhancing the bleaching of wood pulp.
In a further aspect, the present invention provides a method of altering the sensitivity of a xylanase polypeptide to an inhibitor which method comprises modifying one or more amino acid residues of said enzyme selected from amino acid numbers 11, 12, 13, 15, 17, 29, 31, 32, 34, 113, 114, 119, 120, 121, 122, 123, 124 and 175 based on the amino acid numbering of B. subtilis xylanase shown as SEQ ID No. 1, or the equivalent residues in other homologous xylanase polypeptides. Preferably the sensitivity is reduced. . 5
Importantly, our results also show for the first time that xylanase inhibitors play an important role in determining the functionality of xylanase enzymes in a complex system, such as a plant material. By the term “functionality”, we mean the biochemical properties of the xylanase in a given system. These properties include substrate specificity, Ky, and
Vmax kinetic parameters (where appropriate) and the nature of the reaction products obtained by the action of the xylanase in that system. Functionality may also consequently be described in terms of the effect on the physical and/or chemical properties of the plant materials on which the xylanase acts, for example the extent to which the viscosity of the material is altered.
In the same way that variant xylanases may be used in a variety of processing applications, xylanase inhibitors may be used in a variety of processing applications such as bakery, wood pulp processing and cereal processing.
Although in general any molecular techniques mentioned herein are well known in the art, reference may be made in particular to Sambrook et al., Molecular Cloning, A Laboratory
Manual (1989) and Ausubel et al., Short Protocols in Molecular Biology (1999) 4™ Eq,
John Wiley & Sons, Inc.
A. Variant xylanase polypeptides
Xylanase enzymes have been reported from nearly 100 different organisms, including plants, fungi and bacteria. The xylanase enzymes are classified into several of the more than 40 families of glycosyl hydrolase enzymes. The glycosyl hydrolase enzymes, which include xylanases, mannanases, amylases, PB-glucanases, cellulases, and other carbohydrases, are classified based on such properties as the sequence of amino acids, the three dimensional structure and the geometry of the catalytic site (Gilkes, et al., 1991,
Microbiol. Reviews 55: 303-315). : 5 Of particular interest for baking applications are the enzymes classified in Family 11. All of these are xylanases and are known as the "Family 11 xylanases". Some publications refer to these synonymously as the Family G xylanases, but the term “Family 11 xylanases” will be used herein to refer to both Family G and Family 11 xylanases.
Table A lists a number of known Family 11 xylanases. Most of them have a molecular mass of about 21,000 Da. Three of the Family 11 xylanases (Clostridium stercorarium
XynA, Streptomyces lividans XynB, and Thermomonospora fusca XynA) have a higher molecular mass of 31,000 to 50,000 Da. However, these xylanases have a catalytic core sequence of about 21,000 Da similar to the other Family 11 xylanases. The amino acid sequences of the Family 11 xylanases (or, for the larger enzymes, the catalytic core) show a high degree of similarity, usually with more than 40 % identical amino acids in a proper amino acid alignment. The Family 11 xylanases, which are of bacterial, yeast, or fungal origin, share the same general molecular structure.
Figure 2 shows amino acid sequence alignment data in respect of 51 Family 11 xylanases.
TABLE A - Family 11 xylanases
Aspergillus niger Xyn A Aspergillus kawachii Xyn C
Aspergillus tubigensis Xyn A Bacillus circulans Xyn A
Bacillus pumilus Xyn A Bacillus subtilis Xyn A
Cellulomonas fimi Xyn D Chainia spp. Xyn
Clostridium acetobutylicum Xyn B Clostridium stercorarium Xyn A
Fibrobacter succinogenes Xyn C Neocallimastix patriciarum Xyn A
Nocardiopsis dassonvillei Xyn Il Ruminococcus flavefaciens Xyn A
Schizophyllum commune Xyn Streptomyces lividans Xyn B
Streptomyces lividans Xyn C Streptomyces sp. No. 36a Xyn
Streptomyces thermoviolaceus Xyn II Thermomonospora fusca Xyn A . | Trichoderma harzianum Xyn Trichoderma reesei Xyn I
Trichoderma reesei Xyn II Trichoderma viride Xyn
Variant xylanases of the invention
A variant xylanase polypeptide of the invention is typically obtained by modifying a xylanase polypeptide by substituting, deleting or adding one or more amino acid residues within the amino acid sequence of the xylanase polypeptide. Preferably the modification comprises one or more amino acid substitutions. Modification of polypeptide sequences can be carried out using standard techniques such as site directed mutagenesis. The modification may also occur by chemical techniques — such as chemical modification of one or more amino acid residues.
The starting sequence may be a wild type sequence or a non-naturally occurring sequence, for example a derivative that has already been subjected to protein engineering. The
Xylanase sequence to be modified may be from any source, for example a bacterial, fungal 1s or plant source. Preferably the xylanase sequence to be modified is that of a Family 11 xylanase, more preferably a Family 11 xylanase selected from Trichoderma reesei xylanase I, Trichoderma reesei xylanase II, Trichoderma harzianum xylanase,
Trichoderma viride xylanase, Bacillus circulans xylanase A, Bacillus subtilis xylanase A,
Aspergillus niger xylanase A, Aspergillus kawachii xylanase C, Aspergillus tubigensis xylanase A, Streptomyces lividans xylanase B, and Streptomyces lividans xylanase C.
In a particularly preferred embodiment, the xylanase sequence to be modified is the
B subtilis xylanase sequence shown as SEQ ID No. 1 or a homologue thereof. Preferably said homologue has at least 40, 50, 60 or 80% homology over at least 50 or 100 amino acid residues as determined using the GCG Wisconsin Bestfit package (University of
Wisconsin, U.S.A; Devereux ef al., 1984, Nucleic Acids Research 12:387).
Specific modifications that are preferred according to the present invention include one or more amino acid substitutions at positions 11, 12, 13, 15, 17, 29, 31, 32, 34, 113, 114, 119, 120, 121, 122, 123, 124 and 175 based on the amino acid numbering of B. subtilis . 5 Xylanase shown as SEQ ID No. 1, or the equivalent residues in other homologous xylanase polypeptides.
Particularly preferred substitutions include one or more of D11sY, D1IsN, DI1IsF,
DI1sK, D11sS, D11sW, G12gF, G13gF, 115K, N17sK, N17sY, N17sD, N29sK, N29sY,
N29sD, S31sK, S31sY, S31sD, N32sK, G34sD, G34sF, G34sT, Y113sA, Y113sD,
Y1135K, N114sA, N114sD, N114sF, N114sK, D119sK, D119sY, D119sN, G120sK,
G120sD, G120sF, G120sY, G120sN, D121sN, D121sK, D121sF, D121sA, R122sD,
R122¢F, R1225A, T123sK, T123s5Y, T123sD, T124sK, T124sY, T124sD, Q175E,
Q175sS and Q175sL (with reference to the amino acid sequence of B. subtilis xylanase) or their equivalents in other homologous xylanase polypeptides. Further references to specific residues of the B. subtilis xylanase shown as SEQ ID No. 1 will also include their equivalents in other homologous xylanase polypeptides.
A combination of mutations may be carried out, for example mutations at two or more of the above-mentioned residues. Examples of such combinations are presented in the
Examples section herein.
In a further embodiment, the variant polypeptides of the invention may be purified and isolated naturally occurring mutant xylanases. Alternatively, mutant xylanases may be generated by subjecting organisms to mutagens and then screening for individuals comprising mutations in their xylanase genes. Naturally occurring mutants and mutants generated by random mutagenesis may be identified/screened using a variety of techniques such as PCR screening using suitable nucleic acid primers to amplify regions of xylanase genes and sequencing the resulting fragments.
Thus variant polypeptides of the invention include naturally occurring mutant xylanases (purified and isolated from the organisms in which they occur or obtained recombinantly),
mutant xylanases obtained by random mutagenesis and mutant xylanases obtained by site- directed mutagenesis.
Variant polypeptides of the invention may also be subjected to further modifications that : 5 do not necessarily affect sensitivity to inhibitors, including any substitution of, variation of, modification of, replacement of, deletion of or addition of one (or more) amino acids from or to the sequence providing the resultant amino acid sequence retains xylanase activity, preferably having at least substantially the same xylanase activity as the unmodified sequence.
Conservative substitutions may be made, for example according to the Table below.
Amino acids in the same block in the second column and preferably in the same line in the third column may be substituted for each other: [ ALIPHATIC Non-polar Ea a
Polar - uncharged csT™ a
Polar - charged EE
RA —— [wowame | Jarwx -
Polypeptides of the invention also include fragments of the full length sequences mentioned above having xylanase activity.
Polypeptides of the invention may further comprise heterologous amino acid sequences, typically at the N-terminus or C-terminus, preferably the N-terminus. Heterologous sequence may include sequences that affect intra or extracellular protein targeting (such as leader sequences).
Polypeptides of the invention are typically made by recombinant means, for example as described below. However they may also be made by synthetic means using techniques well known to skilled persons such as solid phase synthesis. Polypeptides of the invention may also be produced as fusion proteins, for example to aid in extraction and purification. It may also be convenient to include a proteolytic cleavage site between the fusion protein partner and the protein sequence of interest to allow removal of fusion protein sequences, such as a thrombin cleavage site. Preferably the fusion protein will not hinder the function of the protein sequence of interest.
The use of appropriate host cells is expected to provide for such post-translational modifications as may be needed to confer optimal biological activity on recombinant expression products of the invention.
Polypeptides of the invention may be in a substantially isolated form. It will be understood that the protein may be mixed with carriers or diluents which will not interfere with the intended purpose of the protein and still be regarded as substantially isolated. A polypeptide of the invention may also be in a substantially purified form, in which case it will generally comprise the protein in a preparation in which more than 90%, e.g. 95%, 98% or 99% of the protein in the preparation is a polypeptide of the invention.
Variant polypeptides of the invention have altered sensitivity to xylanase inhibitors compared to the parent xylanase sequence — which may be a corresponding wild type xylanase. Preferably, variant polypeptides have reduced sensitivity to xylanase inhibitors.
The term “altered sensitivity to xylanase inhibitors” means that extent to which the endo-
B-1,4-xylanase activity of a variant polypeptide of the invention is inhibited by the xylanase inhibitor is different to that of the parent xylanase enzyme — which may be the corresponding wild type xylanase. Preferably the extent to which the variant polypeptide is inhibited by the inhibitor is less than that of the parent xylanase enzyme — which may be the wild type protein. This may, for example, be due to a change in the three- dimensional structure of the variant polypeptide such that the inhibitor no longer binds with the same affinity as it does to the parent xylanase enzyme — which may be the wild type enzyme.
The sensitivity of the variant polypeptides of the invention to xylanase inhibitors can be assayed using, for example, the assay described in example 4 and below. A suitable inhibitor for use in the assay is the inhibitor purified from wheat flour in example 1.
Other inhibitors are described below.
Xylanase assay (Endo--1,4-Xylanase activity)
Xylanase samples are diluted in citric acid (0.1 M) - di-sodium-hydrogen phosphate (0.2 M) buffer, pH 5.0, to obtain approx. OD = 0.7 in the final assay. Three dilutions of the sample and an internal standard with a defined activity are thermostated for 5 minutes at 40°C. At time = 5 minutes, 1 Xylazyme tab (crosslinked, dyed xylan substrate) is added to the enzyme solution. At time = 15 minutes (or in some cases longer, depending on the xylanase activity present in the sample) the reaction is terminated, by adding 10 ml of 2% TRIS. The reaction mixture is centrifuged and the OD of the supernatant is measured at 590 nm. Taking into account the dilutions and the amount of xylanase, the activity (TXU, Total-Xylanase-Units) of the sample can be calculated relative to the standard.
Xvlanase inhibitors
As used herein, the term “xylanase inhibitor” refers to a compound, typically a protein, whose role is to control the depolymerisation of complex carbohydrates, such as arabinoxylan, found in plant cell walls. These xylanase inhibitors are capable of reducing the activity of naturally occurring xylanase enzymes as well as those of fungal or bacterial origin. Although the presence of xylanase inhibitors have been reported in cereal seeds (see for example McLauchlan et al 1999a; Rouau and Suget 1998) their impact on the efficacy of xylanase enzymes has not been extensively examined.
McLauchlan et al (1999a) disclose the isolation and characterisation of a protein from wheat that binds to and inhibits two family-11 xylanases. Likewise, WO 98/49278 demonstrates the effect of a wheat flour extract on the activity of a group of microbial xylanases all of which are classified as family 11 xylanases. Debyser et al. (1999) also disclose that endoxylanases from Aspergillus niger and Bacillus subtilis, which are both members of the family 11 Xylanases were inhibited by a wheat xylanase inhibitor called
TAXI. McLauchlan er al (1999b) teach that extracts from commercial flours such as wheat, barley, rye and maize are capable of inhibiting both family 10 and 11 xylanases.
The xylanase inhibitor may be any suitable xylanase inhibitor. By way of example, the : 5 xylanase inhibitor may be the inhibitor described in WO-A-98/49278 and/or the xylanase inhibitor described by Rouau, X. and Surget, A. (1998), McLauchlan, R., et al. (1999) and/or the xylanase inhibitor described in UK patent application number 9828599.2 (filed 23 December 1998), UK patent application number 9907805.7 (filed 6 April 1999) and
UK patent application number 9908645.6 (filed 15 April 1999).
Xylanase inhibitor assay 100 pl of an candidate inhibitor fraction, 250 pl xylanase solution (containing 12 TXU microbial xylanase/ml) and 650 pl buffer (0.1 M citric acid - 02M di-sodium hydrogen phosphate buffer, pH 5.0) are mixed. The mixture is thermostated for 5 minutes at 40.0°C. At time = 5 minutes one Xylazyme tab is added. At time = 15 minutes the reaction is terminated by adding 10 ml 2% TRIS. The reaction mixture is centrifuged (3500 g, 10 minutes, room temperature) and the supernatant is measured at 590 nm. The inhibition is calculated as residual activity compared to the blank. The blank is prepared the same way, except that the 100 pl inhibitor is substituted with 100 pl buffer (0.1 M citric acid - 0.2 M di-sodium hydrogen phosphate buffer, pH 5.0).
Specific xylanase inhibitor
As indicated, a xylanase inhibitor that may be used in accordance with the present invention is the xylanase inhibitor described in UK patent application number 9828599.2 (filed 23 December 1998), UK patent application number 9907805.7 (filed 6 April 1999) and UK patent application number 9908645.6 (filed 15 April 1999).
This endogenous endo-B-1,4-xylanase inhibitor is obtainable from wheat flour. The inhibitor is a di-peptide, having a MW of about 40 kDa (as measured by SDS-PAGE or mass spectrometry) and a pl of about 8 to about 9.5.
Sequence analysis to date has revealed the that the inhibitor has at least one or more of the sequences presented as SEQ ID No. 2, SEQ ID No. 3, SEQ ID No 4, SEQ ID No. 5, SEQ
ID No. 6, SEQ ID No. 7 and/or SEQ ID No. 8. : 5
These inhibitors described in the prior art may also be used in assays to determine the sensitivity of a variant polypeptide of the invention to xylanase inhibitors. They may also be used as described below to modulate the functionality of a xylanase. Polynucleotides
Polynucleotides of the invention comprise nucleic acid sequences encoding the variant polypeptide sequences of the invention. It will be understood by a skilled person that numerous different polynucleotides can encode the same polypeptide as a result of the degeneracy of the genetic code. In addition, it is to be understood that skilled persons may, using routine techniques, make nucleotide substitutions that do not affect the polypeptide sequence encoded by the polynucleotides of the invention to reflect the codon usage of any particular host organism in which the polypeptides of the invention are to be expressed. Polynucleotides of the invention may comprise DNA or RNA. They may be single- stranded or double-stranded. They may also be polynucleotides which include within them synthetic or modified nucleotides. A number of different types of modification to oligonucleotides are known in the art. These include methylphosphonate and phosphorothioate backbones, addition of acridine or polylysine chains at the 3' and/or 5' ends of the molecule. For the purposes of the present invention, it is to be understood that the polynucleotides described herein may be modified by any method available in the art.
Such modifications may be carried out in order to enhance the in vivo activity or life span of polynucleotides of the invention.
Nucleotide vectors and host cells
Polynucleotides of the invention can be incorporated into a recombinant replicable vector.
The vector may be used to replicate the nucleic acid in a compatible host cell. Thus in a further embodiment, the invention provides a method of making polynucleotides of the invention by introducing a polynucleotide of the invention into a replicable vector, introducing the vector into a compatible host cell, and growing the host cell under : 5 conditions which bring about replication of the vector. The vector may be recovered from the host cell. Suitable host cells include bacteria such as E. coli, yeast and fungi.
Preferably, a polynucleotide of the invention in a vector is operably linked to a regulatory sequence which is capable of providing for the expression of the coding sequence by the host cell, i.e. the vector is an expression vector. The term “operably linked” refers to a juxtaposition wherein the components described are in a relationship permitting them to function in their intended manner. A regulatory sequence “operably linked” to a coding sequence is ligated in such a way that expression of the coding sequence is achieved under conditions compatible with the control sequences. The term “regulatory sequences” includes promoters and enhancers and other expression regulation signals.
Enhanced expression of the polynucleotide encoding the polypeptide of the invention may also be achieved by the selection of heterologous regulatory regions, e.g. promoter, secretion leader and terminator regions, which serve to increase expression and, if desired, secretion levels of the protein of interest from the chosen expression host and/or to provide for the inducible control of the expression of the polypeptide of the invention.
Aside from the promoter native to the gene encoding the polypeptide of the invention, other promoters may be used to direct expression of the polypeptide of the invention. The promoter may be selected for its efficiency in directing the expression of the polypeptide of the invention in the desired expression host.
In another embodiment, a constitutive promoter may be selected to direct the expression of the desired polypeptide of the invention. Examples of strong constitutive and/or inducible promoters which are preferred for use in fungal expression hosts are those which are obtainable from the fungal genes for xylanase (x/nA), phytase, ATP-synthetase, subunit 9 (0liC), triose phosphate isomerase (pi), alcohol dehydrogenase (4AdhA),
a-amylase (amy), amyloglucosidase (AG - from the glaA gene), acetamidase (amdS) and glyceraldehyde-3-phosphate dehydrogenase (gpd) promoters.
Examples of strong yeast promoters are those obtainable from the genes for alcohol ’ 5 dehydrogenase, lactase, 3-phosphoglycerate kinase and triosephosphate isomerase.
Examples of strong bacterial promoters are the a-amylase and SP02 promoters as well as promoters from extracellular protease genes.
Hybrid promoters may also be used to improve inducible regulation of the expression construct.
Often, it is desirable for the polypeptide of the invention to be secreted from the expression host into the culture medium from where the polypeptide of the invention may be more easily recovered. According to the present invention, the polypeptide of the invention’s native secretion leader sequence may be used to effect the secretion of the expressed polypeptide of the invention. However, an increase in the expression of the polypeptide of the invention sometimes results in the production of the protein in levels beyond that which the expression host is capable of processing and secreting, creating a bottleneck such that the protein product accumulates within the cell. Accordingly, the present invention also provides heterologous leader sequences to provide for the most efficient secretion of the polypeptide of the invention from the chosen expression host.
According to the present invention, the secretion leader may be selected on the basis of the desired expression host. A heterologous secretion leader may be chosen which is homologous to the other regulatory regions of the expression construct. For example, the leader of the highly secreted amyloglucosidase (AG) protein may be used in combination with the amyloglucosidase (AG) promoter itself, as well as in combination with other promoters. Hybrid signal sequences may also be used with the context of the present invention.
Examples of preferred heterologous secretion leader sequences are those originating from the fungal amyloglucosidase (AG) gene (glaA - both 18 and 24 amino acid versions e.g. from Aspergillus), the a-factor gene (yeasts e.g. Saccharomyces and Kluyveromyces) or the a-amylase gene (Bacillus). . SE
Such vectors may be transformed into a suitable host cell as described above to provide for expression of a polypeptide of the invention. Thus, in a further aspect the invention provides a process for preparing polypeptides according to the invention which comprises cultivating a host cell transformed or transfected with an expression vector as described above under conditions to provide for expression by the vector of a coding sequence encoding the polypeptides, and recovering the expressed polypeptides. Suitable host cells include, for example, fungal cells, such as Aspergillus and yeast cells, such as yeast cells of the genus Kluyveromyces or Saccharomyces. Other suitable host cells are discussed below.
The vectors may be for example, plasmid, virus or phage vectors provided with an origin of replication, optionally a promoter for the expression of the said polynucleotide and optionally a regulator of the promoter. The vectors may contain one or more selectable marker genes. The most suitable selection systems for industrial micro-organisms are those formed by the group of selection markers which do not require a mutation in the host organism. Examples of fungal selection markers are the genes for acetamidase (amdS), ATP synthetase, subunit 9 (0liC), orotidine-5’-phosphate-decarboxylase (pvrA), phleomycin and benomyl resistance (benA). Examples of non-fungal selection markers are the bacterial G418 resistance gene (this may also be used in yeast, but not in fungi), the ampicillin resistance gene (E. coli), the neomycin resistance gene (Bacillus) and the E. coli uidA gene, coding for B-glucuronidase (GUS). Vectors may be used in vitro, for example for the production of RNA or used to transfect or transform a host cell.
A further embodiment of the invention provides host cells transformed or transfected with a polynucleotide of the invention. Preferably said polynucleotide is carried in a vector for the replication and expression of said polynucleotides. The cells will be chosen to be compatible with the said vector and may for example be prokaryotic (for example bacterial), fungal, yeast or plant cells.
Bacteria from the genus Bacillus are very suitable as heterologous hosts because of their - 5 capability to secrete proteins into the culture medium. Other bacteria suitable as hosts are those from the genera Streptomyces and Pseudomonas.
Depending on the nature of the polynucleotide encoding the polypeptide of the invention, and/or the desirability for further processing of the expressed protein, eukaryotic hosts such as yeasts or fungi may be preferred. In general, yeast cells are preferred over fungal cells because they are easier to manipulate. However, some proteins are either poorly secreted from the yeast cell, or in some cases are not processed properly (e.g. hyperglycosylation in yeast). In these instances, a fungal host organism should be selected.
A heterologous host may also be chosen wherein the polypeptide of the invention is produced in a form which is substantially free from other xylanases. This may be achieved by choosing a host which does not normally produce such enzymes.
Examples of preferred expression hosts within the scope of the present invention are fungi such as Aspergillus species and Trichoderma species; bacteria such as Bacillus species,
Streptomyces species and Pseudomonas species; and yeasts such as Kluyveromyces species and Saccharomyces species.
Particularly preferred expression hosts may be selected from Aspergillus niger,
Aspergillus niger var. tubigenis, Aspergillus niger var. awamori, Aspergillus aculeatis,
Aspergillus nidulans, Aspergillus oryzae, Trichoderma reesei, Bacillus subtilis, Bacillus licheniformis, Bacillus amyloliquefaciens, Kluyveromyces lactis and Saccharomyces } cerevisiae.
According to the present invention, the production of the polypeptide of the invention can be effected by the culturing of microbial expression hosts, which have been transformed with one or more polynucleotides of the present invention, in a conventional nutrient fermentation medium.
The fermentation medium can comprise a known culture medium containing a carbon - 5 source (e.g. glucose, maltose, molasses, etc.), a nitrogen source (e.g. ammonium sulphate, ammonium nitrate, ammonium chloride, etc.), an organic nitrogen source (e.g. yeast extract, malt extract, peptone, etc.) and inorganic nutrient sources (e.g. phosphate, magnesium, potassium, zinc, iron, etc.). Optionally, an inducer may be added.
The selection of the appropriate medium may be based on the choice of expression hosts and/or based on the regulatory requirements of the expression construct. Such media are well-known to those skilled in the art. The medium may, if desired, contain additional components favouring the transformed expression hosts over other potentially contaminating microorganisms.
After fermentation, the cells can be removed from the fermentation broth by means of centrifugation or filtration. After removal of the cells, the variant polypeptide of the invention may then be recovered and, if desired, purified and isolated by conventional means.
Organisms
The term “organism” in relation to the present invention includes any organism that could comprise the nucleotide sequence coding for the variant xylanase protein according to the present invention and/or products obtained therefrom, wherein a transcriptional regulatory sequence can allow expression of the nucleotide sequence according to the present invention when present in the organism. Suitable organisms may include a prokaryote, fungus, yeast or a plant. For the xylanase aspect of the present invention, a preferable organism may be a bacterium, preferably of the genus Bacillus, more preferably Bacillus subtilis.
The term “transgenic organism” in relation to the present invention includes any organism that comprises the nucleotide sequence coding for the protein according to the present invention and/or products obtained therefrom, wherein the transcriptional regulatory sequence can allow expression of the nucleotide sequence according to the present invention within the organism. Preferably the nucleotide sequence is incorporated in the genome of the organism.
The term “transgenic organism” does not cover native nucleotide coding sequences in their natural environment when they are under the control of their native promoter which is also in its natural environment.
Therefore, the transgenic organism of the present invention includes an organism comprising any one of, or combinations of, the nucleotide sequence coding for the amino acid sequence according to the present invention, constructs according to the present invention (including combinations thereof), vectors according to the present invention, plasmids according to the present invention, cells according to the present invention, tissues according to the present invention or the products thereof. The transformed cell or organism could prepare acceptable quantities of the desired compound which would be easily retrievable from, the cell or organism.
Transformation of Host Cells/Host Organisms
As indicated earlier, the host organism can be a prokaryotic or a eukaryotic organism.
Examples of suitable prokaryotic hosts include E. coli and Bacillus subtilis. Teachings on the transformation of prokaryotic hosts is well documented in the art, for example see
Sambrook et al (Molecular Cloning: A Laboratory Manual, 2nd edition, 1989, Cold Spring
Harbor Laboratory Press) and Ausubel ef al., Short Protocols in Molecular Biology (1999), 4" Ed., John Wiley & Sons, Inc.
If a prokaryotic host is used then the nucleotide sequence may need to be suitably modified before transformation - such as by removal of introns.
As mentioned above, a preferred host organism is of the genus Bacillus, such as Bacillus subtilis.
In another embodiment the transgenic organism can be a yeast. In this regard, yeasts have also been widely used as a vehicle for heterologous gene expression. The species
Saccharomyces cerevisiae has a long history of industrial use, including its use for heterologous gene expression. Expression of heterologous genes in Saccharomyces cerevisiae has been reviewed by Goodey et al (1987, Yeast Biotechnology, D R Berry et al, eds, pp 401-429, Allen and Unwin, London) and by King et al (1989, Molecular and Cell
Biology of Yeasts, E F Walton and G T Yarronton, eds, pp 107-133, Blackie, Glasgow).
For several reasons Saccharomyces cerevisiae is well suited for heterologous gene expression. First, it is non-pathogenic to humans and it is incapable of producing certain endotoxins. Second, it has a long history of safe use following centuries of commercial exploitation for various purposes. This has led to wide public acceptability. Third, the extensive commercial use and research devoted to the organism has resulted in a wealth of knowledge about the genetics and physiology as well as large-scale fermentation characteristics of Saccharomyces cerevisiae.
A review of the principles of heterologous gene expression in Saccharomyces cerevisiae and secretion of gene products is given by E Hinchcliffe E Kenny (1993, "Yeast as a vehicle for the expression of heterologous genes”, Yeasts, Vol 5, Anthony H Rose and
J Stuart Harrison, eds, 2nd edition, Academic Press Ltd.).
Several types of yeast vectors are available, including integrative vectors, which require recombination with the host genome for their maintenance, and autonomously replicating plasmid vectors.
In order to prepare the transgenic Saccharomyces, expression constructs are prepared by inserting the nucleotide sequence of the present invention into a construct designed for . expression in yeast. Several types of constructs used for heterologous expression have been developed. The constructs contain a promoter active in yeast fused to the nucleotide sequence of the present invention, usually a promoter of yeast origin, such as the GAL!
promoter, is used. Usually a signal sequence of yeast origin, such as the sequence encoding the SUC2 signal peptide, is used. A terminator active in yeast ends the expression system.
For the transformation of yeast several transformation protocols have been developed. For : 5 example, a transgenic Saccharomyces according to the present invention can be prepared by following the teachings of Hinnen et al (1978, Proceedings of the National Academy of
Sciences of the USA 75, 1929); Beggs, J D (1978, Nature, London, 275, 104); and Ito, H et al (1983, J Bacteriology 153, 163-168).
The transformed yeast cells are selected using various selective markers. Among the markers used for transformation are a number of auxotrophic markers such as LEU2, HIS4 and TRP1, and dominant antibiotic resistance markers such as aminoglycoside antibiotic markers, e.g. G418.
Another host organism is a plant. The basic principle in the construction of genetically modified plants is to insert genetic information in the plant genome so as to obtain a stable maintenance of the inserted genetic material.
A transgenic plant of the invention may be produced from any plant such as the seed- bearing plants (angiosperms), and conifers. Angiosperms include dicotyledons and monocotyledons. Examples of dicotyledonous plants include tobacco, (Nicotiana plumbaginifolia and Nicotiana tabacum), arabidopsis (drabidopsis thaliana), Brassica napus, Brassica nigra, Datura innoxia, Vicia narbonensis, Vicia faba, pea (Pisum sativum), cauliflower, camation and lentil (Lens culinaris). Examples of monocotyledonous plants include cereals such as wheat, barley, oats and maize.
Techniques for producing transgenic plants are well known in the art. Typically, either whole plants, cells or protoplasts may be transformed with a suitable nucleic acid . construct encoding a zinc finger molecule or target DNA (see above for examples of nucleic acid constructs). There are many methods for introducing transforming DNA constructs into cells, but not all are suitable for delivering DNA to plant cells. Suitable methods include Agrobacterium infection (see, among others, Turpen ef al., 1993, J.
Virol. Methods, 42: 227-239) or direct delivery of DNA such as, for example, by PEG- mediated transformation, by electroporation or by acceleration of DNA coated particles.
Acceleration methods are generally preferred and include, for example, microprojectile bombardment. A typical protocol for producing transgenic plants (in particular ’ 5 monocotyledons), taken from U.S. Patent No. 5, 874, 265, is described below.
An example of a method for delivering transforming DNA segments to plant cells is microprojectile bombardment. In this method, non-biological particles may be coated with nucleic acids and delivered into cells by a propelling force. Exemplary particles include those comprised of tungsten, gold, platinum, and the like.
A particular advantage of microprojectile bombardment, in addition to it being an effective means of reproducibly stably transforming both dicotyledons and monocotyledons, is that neither the isolation of protoplasts nor the susceptibility to
Agrobacterium infection is required. An illustrative embodiment of a method for delivering DNA into plant cells by acceleration is a Biolistics Particle Delivery System, which can be used to propel particles coated with DNA through a screen, such as a stainless steel or Nytex screen, onto a filter surface covered with plant cells cultured in suspension. The screen disperses the tungsten-DNA particles so that they are not delivered to the recipient cells in large aggregates. It is believed that without a screen intervening between the projectile apparatus and the cells to be bombarded, the projectiles aggregate and may be too large for attaining a high frequency of transformation. This may be due to damage inflicted on the recipient cells by projectiles that are too large.
For the bombardment, cells in suspension are preferably concentrated on filters. Filters containing the cells to be bombarded are positioned at an appropriate distance below the macroprojectile stopping plate. If desired, one or more screens are also positioned between the gun and the cells to be bombarded. Through the use of techniques set forth . herein one may obtain up to 1000 or more clusters of cells transiently expressing a marker gene ("foci") on the bombarded filter. The number of cells in a focus which express the exogenous gene product 48 hours post-bombardment often range from 1 to 10 and average 2 to 3.
After effecting delivery of exogenous DNA to recipient cells by any of the methods discussed above, a preferred step is to identify the transformed cells for further culturing and plant regeneration. This step may include assaying cultures directly for a screenable : 5 trait or by exposing the bombarded cultures to a selective agent or agents.
An example of a screenable marker trait is the red pigment produced under the control of the R-locus in maize. This pigment may be detected by culturing cells on a solid support containing nutrient media capable of supporting growth at this stage, incubating the cells at, e.g, 18°C and greater than 180 uE m? s!, and selecting cells from colonies (visible aggregates of cells) that are pigmented. These cells may be cultured further, either in suspension or on solid media.
An exemplary embodiment of methods for identifying transformed cells involves exposing the bombarded cultures to a selective agent, such as a metabolic inhibitor, an antibiotic, herbicide or the like. Cells which have been transformed and have stably integrated a marker gene conferring resistance to the selective agent used, will grow and divide in culture. Sensitive cells will not be amenable to further culturing.
To use the bar-bialaphos selective system, bombarded cells on filters are resuspended in nonselective liquid medium, cultured (e.g. for one to two weeks) and transferred to filters overlaying solid medium containing from 1-3 mg/l bialaphos. While ranges of 1-3 mg/l will typically be preferred, it is proposed that ranges of 0.1-50 mg/l will find utility in the practice of the invention. The type of filter for use in bombardment is not believed to be particularly crucial, and can comprise any solid, porous, inert support.
Cells that survive the exposure to the selective agent may be cultured in media that supports regeneration of plants. Tissue is maintained on a basic media with hormones for about 2-4 weeks, then transferred to media with no hormones. After 2-4 weeks, shoot development will signal the time to transfer to another media.
Regeneration typically requires a progression of media whose composition has been modified to provide the appropriate nutrients and hormonal signals during sequential . developmental stages from the transformed callus to the more mature plant. Developing plantlets are transferred to soil, and hardened, e.g., in an environmentally controlled chamber at about 85% relative humidity, 600 ppm CO,, and 250 pE m? 5! of light.
Plants are preferably matured either in a growth chamber or greenhouse. Regeneration will typically take about 3-12 weeks. During regeneration, cells are grown on solid media in tissue culture vessels. An illustrative embodiment of such a vessel is a petri dish.
Regenerating plants are preferably grown at about 19°C to 28°C. After the regenerating plants have reached the stage of shoot and root development, they may be transferred to a greenhouse for further growth and testing.
Genomic DNA may be isolated from callus cell lines and plants to determine the presence of the exogenous gene through the use of techniques well known to those skilled in the art such as PCR and/or Southern blotting.
Several techniques exist for inserting the genetic information, the two main principles being direct introduction of the genetic information and introduction of the genetic information by use of a vector system. A review of the general techniques may be found in articles by Potrykus (Annu Rev Plant Physiol Plant Mol Biol [1991] 42:205-225) and
Christou (Agro-Food-Industry Hi-Tech March/April 1994 17-27).
Thus, in one aspect, the present invention relates to a vector system which carries a construct encoding a variant xylanase polypeptide according to the present invention and which is capable of introducing the construct into the genome of a plant.
The vector system may comprise one vector, but it can comprise at least two vectors. In the case of two vectors, the vector system is normally referred to as a binary vector system. Binary vector systems are described in further detail in Gynheung An et al. (1980), Binary Vectors, Plant Molecular Biology Manual A3, 1-19.
One extensively employed system for transformation of plant cells with a given promoter or nucleotide sequence or construct is based on the use of a Ti plasmid from
Agrobacterium tumefaciens or a Ri plasmid from Agrobacterium rhizogenes (An et al. (1986), Plant Physiol. 81, 301-305 and Butcher D.N. ef al. (1980), Tissue Culture
Methods for Plant Pathologists, eds.: D.S. Ingrams and J.P. Helgeson, 203-208).
Several different Ti and Ri plasmids have been constructed which are suitable for the construction of the plant or plant cell constructs described above.
B. Uses
In a general sense, a variant xylanase of the invention may be used to alter, for example reduce, the viscosity derived from the presence of hemicellulose or arabinoxylan in a solution or system comprising plant cell wall material. Typically said plant cell wall materials will comprise one or more xylanase inhibitors.
Specifically, a variant xylanase of the invention may be used in processing plant materials for use as foodstuffs, such as animal feed, in starch production, in baking and in the processing of wood pulp to make paper.
Preparation of foodstuffs
A variant xylanase of the invention may be used to process plant materials such as cereals that are used in foodstuffs including animal feed. As used herein, the term “cereal” means any kind of grain used for food and/or any grass producing this grain such as but not limited to any one of wheat, milled wheat, barley, maize, sorghum, rye, oats, triticale and rice or combinations thereof. In one preferred embodiment, the cereal is a wheat cereal.
The xylan in the food and/or feed supplement is modified by contacting the xylan with the variant xylanase of the present invention.
As used herein, the term “contacting” includes but is not limited to spraying, coating, impregnating or layering the food and/or feed supplement with the variant xylanase enzyme of the present invention.
In one embodiment, the food and/or feed supplement of the present invention may be prepared by mixing the variant xylanase enzyme directly with a food and/or feed supplement. By way of example, the variant xylanase enzyme may be contacted (for example, by spraying) onto a cereal-based food and/or feed supplement such as milled wheat, maize or soya flour.
It is also possible to incorporating the variant xylanase enzyme it into a second (and different) food and/or feed or drinking water which is then added to the food and/or feed supplement of the present invention. Accordingly, it is not essential that the variant xylanase enzyme provided by the present invention is incorporated into the cereal-based food and/or feed supplement itself, although such incorporation forms a particularly preferred aspect of the present invention.
In one embodiment of the present invention, the food and/or feed supplement may be combined with other food and/or feed components to produce a cereal-based food and/or feed. Such other food and/or feed components may include one or more other (preferably thermostable) enzyme supplements, vitamin food and/or feed supplements, mineral food and/or feed supplements and amino acid food and/or feed supplements. The resulting (combined) food and/or feed supplement comprising possibly several different types of compounds can then be mixed in an appropriate amount with the other food and/or feed components such as cereal and protein supplements to form a human food and/or an animal feed.
In one preferred embodiment, the food and/or feed supplement of the present invention can be prepared by mixing different enzymes having the appropriate activities to produce an enzyme mix. By way of example, a cereal-based food and/or feed supplement formed from e.g. milled wheat or maize may be contacted (e.g. by spraying) either simultaneously or sequentially with the xylanase enzyme and other enzymes having appropriate activities. These enzymes may include but are not limited to any one or more of an amylase, a glucoamylase, a mannanase, an a galactosidase, a phytase, a lipase, a glucanase, an-arabinofuranosidase, a pectinase, a protease, a glucose oxidase, a hexose oxidase and a xylanase. Enzymes having the desired activities may for instance be mixed with the xylanase of the present invention either before contacting these enzymes with a cereal-based food and/or feed supplement or alternatively such enzymes may be contacted simultaneously or sequentially on such a cereal based supplement. The food and/or feed supplement is then in turn mixed with a cereal-based food and/or feed to prepare the final food and/or feed. It is also possible to formulate the food and/or feed supplement as a solution of the individual enzyme activities and then mix this solution with a food and/or feed material prior to processing the food and/or feed supplement into pellets or as a mash.
Bakery products
The present invention provides the use of a variant xylanase polypeptide of the invention in a process for preparing a foodstuff. Typical bakery (baked) products in accordance with the present invention include bread - such as loaves, rolls, buns, pizza bases etc. - pretzels, tortillas, cakes, cookies, biscuits, crackers etc. The preparation of foodstuffs such as bakery products is well know in the art. Dough production, for example, is described in example 2. The use of variant xylanases of the invention to alter the viscosity of a flour slurry in described in the example 5.
Starch production
A variant xylanase of the invention may also be used in starch production from plant materials derived from cereals and tubers, such as potatoes.
Processing of wood pulp
A variant xylanase of the invention may also be used in processing wood pulp, for example in the preparation of paper.
As discussed above, we have shown that a major determinant of xylanase functionality is the presence of endogenous inhibitors in plant material. Consequently, although one method for altering xylanase functionality is to modify a xylanase to change its sensitivity ’ 5 to endogenous inhibitors, another method would be to vary the amount and/or type of inhibitor present in the plant material. Thus, the present invention also provides the use of a xylanase inhibitor to alter the functionality of a xylanase and consequently the use of a Xylanase inhibitor in the methods of processing plant materials described above.
The present invention will now be further described with reference to the following examples which are intended to be illustrative only and non-limiting.
Example 1 - Purification and characterisation of wheat endogenous xylanase inhibitor. 2 kg wheat flour (Danish reform, batch 99056) was extracted with water, using a flour:water ratio of 1:2, during 10 minutes of stirring. The soluble endogenous xylanase inhibitor was separated from the flour-water slurry by centrifugation. The extraction and centrifugation was performed at 4°C. The inhibitor was purified from the water extract by the following chromatographic techniques and concentration techniques: HPLC-SEC,
HPLC-CIEC, rotary evaporation, HPLC-HIC, HPLC-SEC and rotary evaporation. The xylanase inhibitor could be monitored and quantified during purification, using the following quantification method.
Inhibitor quantification method 1 XIU (Xylanase Inhibitor Unit) is defined as the amount of inhibitor that decreases
TXU to 0.5 TXU under the conditions described below. .
The xylanase used in this assay is Bacillus subtilis wild type xylanase.
250 pl xylanase solution containing 12 TXU/ml, approx. 100 pl xylanase inhibitor . solution and citric acid (0.1 M) - di-sodium-hydrogen phosphate (0.2 M) buffer, pH 5, to react a reaction volume of 1000 ul is pre-incubated for 5 minutes at 40°C. Att =5 ‘ 5 minutes, 1 Xylazyme (Megazyme, Ireland) tablet is added to the reaction mixture. Att= 15 minutes the reaction is terminated, by addition of 10 ml 2 % TRIS/NaOH, pH 12. The solution is filtered and the absorbency of the supematant is measured at 590 nm. By choosing several different concentrations of inhibitor in the above assay, it is possible to create a plot of OD versus inhibitor concentration. Using the slope (2) and intercept (b) from this plot and the concentration of the xylanase it is possible to calculate the amount of XIU in a given inhibitor solution (equation 1).
Equation 1 amount of XIU in solution = ((b/2)/-a)/ TXU
From the endogenous xylanase inhibitor purification, the following inhibitor yield was recovered (table 1).
Table 1. Wheat endogenous xylanase inhibitor recovery after purification.
Purified inhibitor 4658/ml 419.220
The inhibitor sample was pure and free from wheat endogenous xylanolytic activities.
Example 2 - Fractionation and reconstruction of wheat flour free of Xylanase inhibitor and xylanases functionality in this flour as a function of added xylanase . inhibitor. ' 5 Flour fractionation and reconstitution
The flour used was: Danish Reform flour, batch No 99056. The fractionation, inhibitor inactivation and reconstitution were as follows:
A simple dough was made by mixing 1600 gram flour, with optimal water addition, according to a baker’s absorption at 500 BU and mixing time according to Farinograph results. This resulted in 2512 gram dough. The gluten was manually washed out from the dough, using a water dough ratio of approx. 5:1. The water used was pre-chilled to 4°C to prevent further enzyme activity in the dough. The resulting wash-water contained the soluble proteins (including the xylanase inhibitor), lipids, non-starch polysaccharides and starch. The starch and other non-soluble components were separated from the wash-water by centrifugation (5000 g, 10 minutes, 10°C). To inactivate the endogenous xylanase inhibitor in the wash-water, the supernatant from the centrifugation was boiled for three minutes using a heat-evaporator.
All three fractions (gluten, starch and solubles) were frozen in flasks and placed in a freeze dryer. After drying, the fractions were weighed, grounded using a mortar and pestle, coffee mill and sieved through a 250 pum sieve. All fractions were weighed again and flour was reconstituted, based on the ratios obtained after fractionation.
Enzymes
The xylanases listed in table 2 have been used in the study. The xylanases are purified, } meaning no other xylonolytic activity is present in the sample.
Table 2. Xylanases used in the study and activity, TXU.
CL CN
Xylanase assay (Endo-B-1.4-Xylanase activity)
Xylanase samples are diluted in citric acid (0.1 M) - di-sodium-hydrogen phosphate (0.2 M) buffer, pH 5.0, to obtain approx. OD = 0.7 in the final assay. Three dilutions of the sample and an internal standard with a defined activity are thermostated for 5 minutes at 40°C. At time = 5 minutes, 1 Xylazyme tab (crosslinked, dyed xylan substrate) is added to the enzyme solution. At time = 15 minutes (or in some cases longer, depending on the Xylanase activity present in the sample) the reaction is terminated, by adding 10 ml of 2% TRIS. The reaction mixture is centrifuged and the OD of the supernatant is measured at 590 nm. Taking into account the dilutions and the amount of xylanase, the activity (TXU, Total-Xylanase-Units) of the sample can be calculated relative to the standard.
Baking trials
Baking trials were done with (1.44 x initial inhibitor level in Danish Reform flour, batch
No 99056) and without addition of purified endogenous xylanase inhibitor to the reconstituted flour, respectively. The baking trials were done using the xylanases listed in’ table 2 and the compositions listed in table 3..
Table 3. Composition of dough made within the baking trials.
ENC
LE CL J
Fp pw
CO
CE SR
Dough analysis
The dough were analysed with respect to:
Stickiness
Dough stickiness was measured on a TX-XT2 system (Stable Micro Systems) using a
SMS Dough Stickiness Cell according to the method described by Chen And Hoseney (Lebensmittel Wiss u.- Technol., 28, 467-473. 1995).
Viscosity analysis of dough liquid
The viscosity of extracted dough liquid was measured using a Brookfield viscosimeter after extraction.
Pentosan analysis of dough liquid
Solubilised pentosan was measured in the dough liquid using the method of Rouau and
Surget (Carbohydrate polymers, 24, 123-132, 1994).
RESULTS
] Flour fractionation and reconstitution
The fractionation and reconstitution of the dough resulted in 168.15 grams of freeze dried 5s gluten, 111.13 grams of freeze dried soluble fraction and 1143.56 grams of freeze dried starch.
Inhibitor quantification in flour
Using the inhibitor quantification method, the inhibitor level in the 99056 flour and the reconstituted flour could be detected. The results from these analyses are listed in table 4.
Table 4. Results from inhibitor quantification in native flour (99056) and reconstituted flour.
Inhibitor concentration, XIU/g flour
Comparing the inhibitor level in the two portions of flour a 93% (100 - (42XIU/590XIU) x 100 %)) decrease of inhibitor level in the reconstituted flour is shown.
Baking trials
The results from the baking trial are listed in tables 5 and 6.
Table 5. Data from baking trials with reconstituted flour, xylanase and +/- xylanase inhibitor addition. Std. dev., % represents the standard deviation over two days of } baking.
I a i 5 Ril ml/gram
IC CS 1 FM
I J ALL
The standard deviation shown in table 5 reflects the dough handling properties of the tested dough. The dough made without the endogenous xylanase inhibitor (42 XIU), were very difficult to handle. The standard deviation for these doughs are in the area of 3 to 12.5 %. Compared to the dough with the inhibitor added, this is quite high. If these standard deviations are compared with the actual changes in the bread volume, it can be seen that the figures are approximately the same value. This means that we can not conclude anything about the absence of the inhibitor’s influence on the bread volume. If we look at the dough made with addition of the endogenous xylanase inhibitor (850 XIU) in table 5, we can see that we were able to produce bread from the reconstituted flour in a reproducible way over a two day period. The standard deviation was within the area of 0.05 to 4.2 %, which is acceptable. From table 6 it can be seen, that the xylanases all increased the volume of the baked bread.
Table 6. Volume increase in bread baked from reconstituted flour as a function of xylanase and xylanase inhibitor addition.
TXU (Inh., XTU/50g |Avg. spec. voli Volume increase as
I
EH NL
Come [vw aw | ow
What can be deduced from table 5 and table 6, is that the absence of the xylanase inhibitor in the flour made the handling of the dough very difficult. Therefore, what may seem as a positive response in volume by addition of inhibitor in table 6, probably can be explained by the high standard deviation in the dough lacking the inhibitor, due to difficult handling properties. Furthermore, it can be concluded that all the xylanases tested increased the bread volume significantly compared to the blank control.
Stickiness
The same dough, that was used for the baking trials, was used for stickiness measurements. The results are listed in table 7.
Table 7. Data representing stickiness as a function of time, xylanase and xylanase inhibitor addition to reconstituted flour.
TXU Inh., Avg. stickiness after Avg, stickiness a [TEST AE
I NI EC IN EA we | 0 [we | am [as
The results in table 7 clearly indicate the influence of the inhibitor that was observed in the experiment. The dough with a low level of xylanase inhibitor in combination with xylanase, was very difficult to handle and mould. However, when the inhibitor was added, the dough became dry and very easy to handle. As can be seen from table 7, addition of the 990202 xylanase in combination with the inhibitor decreased the stickiness. The dough became drier.
Table 7 also shows that there is only a small effect of time on the stickiness. It seems that the xylanases act very rapidly. Within the first 10 minutes most of the arabinoxylan is modified when the first xylanase (B. sub) is added. The second xylanase tested (4. nig), seems to act less rapidly. A function of time can easily be observed using this xylanase. 5s This is also the xylanase that shows the least effect as a function of inhibitor level when analysed on stickiness.
Dough Viscosity
The dough viscosity and the pentosan analysis results were obtained from the same extraction of dough prepared from reconstituted flour added xylanase and xylanase inhibitor. This dough was analysed after two proofing times, 30 and 120 minutes.
The results of the viscosity analysis are presented in table 8.
Table 8. Data representing dough liquid viscosity as a function of time, xylanase and xylanase inhibitor addition to reconstituted flour.
I al a 3 cP, 30 min proofing | cP, 120 min proofing
Control | 0 | 4 [521 [55
B.sub | 7500 [ 80 | 903 | 11.09 [Control | 0 | 80 [ ~~ 5906 [| ~~ 695
As can be seen from table 8 the inhibitor has a significant effect on the functionality of the xylanases. Without addition of the inhibitor, the arabinoxylan is being de-polymerised to
Low Molecular Weight (LMW) arabinoxylan with a low viscosity. Addition of inhibitor prevents this very extensive de-polymerisation of the arabinoxylan.
Pentosan analysis of dough liquid
The results from the pentosan (arabinoxylan) analysis of the dough liquid are presented in table 9.
Table 9. Data representing pentosan solubilisation as a function of time, xylanase and xylanase inhibitor addition to reconstituted flour. = TXU Inh., Avg. Pentosan, %, | Avg. Pentosan, %,
X1U/50¢ 30 min proofing 120 min proofing
Cool | 0 [ 42 | 0.387 0.458 7500 0.766 0.819 7500 0.719 0.798 7500 0.410 0.544 7500 0.560 0.673 [ Control [| 0 [| 850 | 0.400 0.528
As can be seen from the results in table 9, the addition of endogenous xylanase inhibitor decreased the solubilisation of the arabinoxylan. When evaluated after 30 minutes proofing time, the amount of arabinoxylan solubilised in absence of the inhibitor is almost twice the amount as in presence of the inhibitor. Calculated on the basis of the relating control samples, the solubilisation is much higher in absence of the inhibitor, as illustrated in the following example: (0.766- 0.387)/(0.410 - 0.400) = 37.9 times higher solubilisation
The above example was calculated on basis of solubilisation of arabinoxylan using the
Bacillus xylanase, 30 minutes proofing and +/- inhibitor.
Example 3 - Site-directed mutagenesis on xylanases.
Specific mutants of Bacillus subtilis xylanase may be obtained by site directed mutagenesis of the wild type enzyme, by the use of any of a number of commercially available mutagenesis kits. An example of how to obtain the D11F mutant using the
Quick Exchange kit, available from Stratagene Cloning Systems, 11011 North Torrey
Pines Road, La Jolla, CA 92037, USA is given below :
The DNA sequence encoding Bacillus subtilis xylanase A has been published by Paice et al., 1986.
The sequence of the coding region is as follows, with the sequence encoding the mature part of the protein shown in capitals: catatgtttaagtttaaaaagaatttcttagttggattatcggcagetttaatgagtatt . 5 agcttgttttcggcaaccgectctgcaGCTAGCACAGACTACTGGCAAAATTGGACTGAT
GGGGGCGGTATAGTAAACGCTGTCAATGGGTCTGGCGGGAATTACAGTGTTAATTGGTCT
AATACCGGAAATTTTGT TGTTGGTAAAGGTTGGACTACAGGTTCGCCATTTAGGACGATA
AACTATAATGCCGGAGTTTGGGCGCCGAATGGCAATGGATATT TAACTTTATATGGTTGG
ACGAGATCACCTCTCATAGRATATTATGTAGTGGAT TCATGGGGTACTTATAGACCTACT
GGAACGTATAAAGGTACTGTAAAAAGTGATGGGGGTACATATGACATATATACAACTACA
CGTTATARCGCACCTTCCATTGATGGCGATCGCACTACTTTTACGCAGTACTGGAGTGTT
CGCCAGTCGAAGAGACCAACCGGAAGCAACGCTACAATCACTTTCAGCAATCATGTGAAC
GCATGGAAGAGCCATGGAATGAATCTGGGCAGTAATTGGGCTTACCARGTCATGGCGACA
GAAGGATATCAAAGTAGTGGAAGTTCTAACGTAACAGTGTGGTAA
The part of the gene encoding the mature part of the wild type enzyme may be expressed intracellularly in E.coli by methods well known to people skilled in the art of molecular biology. For example : 1. Generating a copy of the capitalised part of the above described gene by use of the
Polymerase Chain Reaction (PCR) with an added Ndel restriction enzyme site (CATATG) before the GCTAGCACA and an added HindIII restriction site (AAGCTT) after the GTGTGGTAA. 2. Inserting the resultant modified copy of the gene by use of the above mentioned enzymes into the expression vector pET24a(+), which can be obtained from Novagen,
Inc. 601 Science Drive, Madison, WI 53711, USA. 3. Transforming into a suitable E.coli strain and expression by fermentation as described by the vendor of pET24a(+). -Our D11F mutant enzyme may be obtained by using the “Quick Exchange” mutagenesis kit according to the manufacturer, and using the above described Bacillus subtilis wild type xylanase-pET24a(+) construct and the following PCR mutagenesis primers :
Sense primer:
CTACTGGCAAAATTGGACTTTTGGAGGAGGTATAGTAAACGCTG
Antisense primer :
CAGCGTTTACTATACCTCCTCCAAAAGTCCAATTTTGCCAGTAG
The mutant enzyme is expressed and purified using the same protocols as for the wild type enzyme.
Example 4 - Inhibition studies of xylanase mutants.
Xylanase mutants expressed in E.coli (see Example 3) were fermented and purified (meaning no other xylanolytic activity was present in the purified preparation) using a de- salting step and a cation exchange chromatography step.
These pure xylanase mutant preparations were diluted to 12 TXU/ml using 0.1 M citric acid - 0.2 M di-sodium-hydrogen phosphate, pH 5.0 and used in the following assay.
A stable inhibitor preparation was made according to the protocol described in Example 1. This stable inhibitor preparation is used as stock for all xylanase-xylanase inhibitor studies. Using the inhibitor quantification method described in example 1, the inhibitor preparation was analysed to contain 126 XIU/ml.
Assay
To 250 pl diluted xylanase mutant preparations, are added 0, 10, 25, 50 or 100 pl inhibitor preparation, respectively. To these inhibitor-xylanase mixtures were added 0.1 M citric acid - 0.2 M di-sodium-hydrogen phosphate, pH 5.0 making the end-volume 1000 pl.
These reaction mixtures were pre-incubated for 5 minutes at 40°C. Hereafter 1 xylazyme tablet (Megazyme, Ireland) were added to all inhibitor-xylanase mixtures. After 10 minutes of incubation at 40°C, the reactions were terminated, by adding 10 ml 2%
Tris/NaOH, pH 12.0. The mixtures were centrifuged and the liberated blue colour from the substrate was measured at 590 nm.
The results are presented in table 10.
Table 10. Relative inhibition of xylanase mutants and parent xylanase (here wildtype } enzyme) as a function of xylanase inhibitor.
MutantID Jo 126 [315 [63 [126 __| |" |Reltiveinhibition,%
Wildype [100 77 a8 9 3 rr 1 pity froo fio lita Ti26 [124
DUN Jioo fo3 — [2 [53 P32
DUK ~~ fioo fies iz Jz file pus fio Jog 81 160 [38 puw_ foo ~~ Tor 188 J70 so]
G34T Joo Joo ~~ Joo ~~ Jos [86 visa fio0 foe [so Jeo Jaz
Yiisb hoo fo6 181 3 Jas
Y113K [100 io3 [8s ~~ 3 ~~ J4a7
NI14A roo Jso 49 © J28 © [2
NID 100 Js4 ~~ [57 ~~ [30 Po
DI2IN _ [i00 so [36 Tie Jia
Di2iF foo Jor 85 ~~ 72 Jeo
Di21A ~~ Jioo 81 Iso To7 Pi
R122D [100 85 Iso ~~ Jar [28
RIF J100 Jo3 ~~ J74 Is8 ~~ Is8
R122A 1100 78 46 [33 = 26
Qi7sE ftoo 187 [so Jao [31
GI2F [100 Juio fio Jioo [92 sk f100 Js4 Jaz J28 P33
Nok Jioo ls2 Jo 0 Tio 4
Gl2ok fio 8s fsa Joo 2
Gi2oD fioo js4 Ja7 Joa fig
Gio Jioo J7r [3s he fis
Gi2oy ~~ fioo fer Jao i816
GI20N [100 184 ~~ 149 ~~ Joo ~~ [23
Dik ~~ [100 Jo4 67 lao [26 |]
Di1oy ~~ Jioo Jg7 so 0 [p88 0 Jo2 |]
DION [100 for [74 ~~ a4 ~~ Jp2 |]
Ti23k Ji00 180 Ja J30 Jos
Com23y Joo so Jar fog 0 P7
T123b too Jes [36 Jo N17
Ti24k jroo fio Joo f753 Is7
Ti24D jroo J&7 [52 [32 Jas]
NIK Ti00 Jes Jag [351 Joe |]
NI7Y fio J; laa p39]
NID Too Joo sr [50 pa ssty fio fs so Jor 2 ssp loo J75 52 Bo pa
DIFRI22D [100 110 Tin filo [109
DUF/G34D_ Jio0 Jio4 — fio6 [103 Jioa
From the results in table 10, it can be seen the xylanase mutants D11Y, D11F, D11K,
D11F/R122D and D11F/G34D are uninhibited by the wheat endogenous xylanase inhibitor. These xylanase mutants would be expected to act more aggressively/specifically on the soluble arabinoxylan, compared to the other xylanase mutants or other xylanases. They would therefore be superior in applications where a decrease in viscosity (as a function of HMW arabinoxylan) is wanted.
Example 5 - Functionality studies of xylanase mutants.
Xylanase mutants expressed in E. coli (see Example 3) were fermented and purified (meaning no other xylanolytic activity were present in the purified preparation).
These pure xylanase mutant preparations were diluted to 400 TXU/ml using water and used in the following assay.
Assay 200 ml 30 % (w/w) flour slurry was made using water (thermostated to 25°C), by stirring for 5 minutes. 60.0 ml of this flour slurry is poured into a Ford-cup, and the time for drainage of 50.0 ml is measured. This measurement is the blank measurement. The 60.0 : ml flour slurry is poured back and 1000 pi diluted xylanase mutant preparation is added to the flour slurry under stirring. After 2, 5, 10 and 20 minutes, 60.0 ml is poured into the
Ford-cup, and the drainage time for 50.0 ml is recorded. Each measurement were done in triplicate. .
The results are presented in table 11.
Table 11. Relative viscosity of flour slurry as a function of xylanase mutant and parent xylanase (here wild type xylanase)
I i minutes
Mutant Jo 2 [5 fio Jao
I 2 change, %
Wildype ~~ Jioo Tii2 [120 [i131 [141
INR I EE I RE
Dity ~~ Jioo Jor jo3 83 755
DUN Too fiz Tes Tio [136
DIF Joo Jo3 [87 178 165
DuUwW_ fio0 fies nis Ti2i [122
G34D [too [iio 120 [128 Ji24
G34F Jreo [rin 126 [128 Tie6
G4T Tio fio es Tur [ioe]
Y113D J100 frie 127 24 [4
Yisk Joo fils hes Jizi Jus
Naa Jioo fry fis Tioz fist
Nip f100 [125 N44 iz [170
NtiaF f1o0 iz iio Tist [iso
N[K 100 i19 1129 fiat [147
DI2IN 100 (104 113 [106 [104
DI2IF 100 for Tiny Jig Tar
RI22F [100 [127 ~~ Ti44 T1500 [160
QI75SE 100 fit6 ~~ [134 Ji42 [149
Qi7ss Jio0 fio m3 Jiar {129
N32k foo fo7 Jeg Jior Jio1
Gi2oD_ fioo fitz 122 J120 [126
Gi2oy ~~ Jioo jio6 [106 [108 li26
Gl2oN fio filo 123 fio 141
Diloy Jioo fez Jie fiir Jue]
T124K fieo [ii7 [131 Ji28 J127
T1240 Jroo Tio3 Tito Juin Jus
N17K
Ni7y fioo hoz (102 [108 10g
N17D 00 J120 N31 i135 lias : N29K 100 Jos loo Tico fio4
N29Y poo jus fiz N32 Tes
N29D 100 Joa hoa Jus fur s3ty fio [iio [ris 122 [137
S50 fio Jo Tos lieo [no
DIIFRI22D J100 Jor 9 182 ~~ 717
DIF/G34D Joo fo6 ~~ fo3 fsa ~~ 80
Example 6. Site-directed mutation in the active site of Bacillus subtilis xylanase A, does not influence the xylanase : xylanase inhibitor interaction.
A residue in the active site of the Bacillus subtilis wildtype xylanase A enzyme was altered by a site-directed mutation (see ex. 3) In the mutated residue (Y166F) a potential hydrogen bond is lost. The mutant xylanase, was expressed in E. coli, fermented and purified. Hereafter, the mutant was investigated for its interaction with the xylanase inhibitor (see example 4).
As can be seen below (table 12), the exchange of an amino acid in the active site, did surprisingly not have any effect on interactions with the xylanase inhibitor as compared to the Bacillus subtilis wildtype xylanase enzyme.
Table 12. Relative inhibition of Bacillus subtilis wildtype xylanase and the xylanase mutant Y166F. 1 um | OT xylanase] of 126] 31s] 63] 126] ~~ [Relativeinhibiton,%
Wildype | 100] 75] 40) 24] 20] : vieeF | 100] 74] 39( 22] 20]
Hence, in summary the experiment described above shows a site-directed mutation in the active site of the Bacillus subtilis xylanase A, which mutation does not influence the xylanase’s interactions with the xylanase inhibitor.
Example 7. Site-directed mutation in family 11 xylanases other than the Bacillus subtilis xylanase A, influencing the xylanase - xylanase inhibitor interactions.
D19 residue of the Thermomyces lanuginosus xylanase A enzyme was mutated to F19 by site-directed mutagenesis. DI19 corresponds to D11 residue in the Bacillus subtilis xylanase (SEQ ID NO. 1). Thermomyces lanuginosus xylanase A gene is described as
SEQ ID NO. 9.
The primers for PCR construction of the D19F mutant may be the following :
Sense primer :
GGTTATTACTATTCCTGGTGGAGTTTTGGAGGAGCGCAGGCCACG
Antisense primer :
CGTGGCCTGCGCTCCTCCAAAACTCCACCAGGAATAGTAATAACC
The obtained mutant xylanase (D19F), was expressed in E. coli, fermented and purified.
Hereafter, the mutant and the Thermomyces lanuginosus wildtype xylanase A was investigated for to its interaction with the xylanase inhibitor (see example 4). As can be seen from the results in table 13, the D19F mutant of the Thermomyces lanuginosus xylanase A is significantly less inhibited by the xylanase inhibitor as compared to the
Thermomyces lanuginosus wildtype xylanase A.
Table 13. Relative inhibition of Thermomyces lanoginosus wildtype xylanase A (TLX) and the Thermomyces lanoginosus mutant xylanase, D19F (D19F). ll we ff] xylanase] of 126] 31s] 63] 12]
Hence, in summary the experiment described above shows a site-directed mutation in the
Thermomyces lanuginosus xylanase A. The results show that a mutation introducing a substitution of an amino acid on the surface of the xylanase molecule (analogue to the 5s DIIF in B. subtilis) changes the xylanase:xylanase inhibitor interactions. Thus, our invention (i.e. that surface residues control the level of inhibition of xylanase) holds true for xylanases that are homologous to the B. subtilis xylanase.
In summary, the present invention provides a means for altering the sensitivity of a
Xylanase enzyme to a xylanase inhibitor.
All publications mentioned in the above specification are herein incorporated by reference. Various modifications and variations of the described methods and system of the present invention will be apparent to those skilled in the art without departing from the scope and spirit of the present invention. Although the present invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments.
Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in biochemistry and biotechnology or related fields are intended to be within the scope of the following claims.
Courtin, C., Roelants, A. and Delcour, J.. (1999). Fractionation-reconstitution experiments provide insight into the role of endoxylanases in bread-making. Journal of : 5 Agricultural and Food Chemistry. 47. 1870-1877.
D’Appolonia, B.L. and MacArthur, L.A. (1976). Comparison of bran and endosperm pentosans in immature and mature wheat. Cereal Chem. 53. 711-718.
Debyser, W. and Delcour, J. A. (1998). Inhibitors of cellolytic, xylanolytic and B- glucanolytic enzymes. WO 98/49278.
Hazlewood, G. P. and Gelbert, H. J. (1993). Recombinant xylanases. PCT application.
WO 93/25693. ‘
Ingelbrecht, J. A., Verwimp, T. and Delcour, J. A. (1999). Endoxylanases in durum wheat semolina processing: solubilisation of arabinoxylans, action of endogenous inhibitors and effects on rheological properties. J. Agri. Food Chem.
Jacobsen, T. S., Heldt-Hansen, H. P., Kofod, L. V., Bagger, C. and Miillertz, A. (1995). Processing plant material with xylanase. PCT application. WO 95/23514.
Kormelink, F. J. M. (1992). Characterisation and mode of action of xylanases and some accessory enzymes. Ph.D. Thesis, Agricultural University Wageningen, Holland (175 pp., English and Dutch summaries).
McLauchlan, R., Garcia-Conesa, M. T., Williamson, G., Roza, M., Ravestein, P. and
MacGregor, A. W.. (1999a). A novel class of protein from wheat which inhibits xylanases. Biochem.J.. 338. 441-446.
McLauchlan, R, Flatman, R et al (1999) Poster Presentation from meeting at University of
Newcastle (1999) April 11%-April 17". Xylanase inhibitors, a novel class of proteins from cereals.
Montgomery, R. and Smith, F. (1955). The Carbohydrates of the Gramineae. VII. The constitution of a water soluble hemicellulose of the endosperm of wheat (Triticum vulgare). J. Am. Chem. Soc. 77. 3325 - 3328.
Paice, M.G., Bourbonnais, R., Desrochers, M., Jurasek, L. and Yaguchi, M. (1986) : A
Xylanase Gene from Bacillus subtilis: Nucleotide Sequence and Comparison with B. pumilus Gene. Arch. Microbiol. 144,201-206.)
Rouau, X. (1993). Investigations into the effects of an enzyme preparation fro baking on wheat flour dough pentosans. J. Cereal Science. 18. 145-157.
Rouau, X., El-Hayek, M-L. and Moreau, D. (1994). Effect of an enzyme preparation containing pentosanases on the bread-making quality of flour in relation to changes in pentosan properties. J. Cereal Science. 19. 259-272.
Slade, L., Levine, H., Craig, S., Arciszewski, H. and Saunders, S. (1993). Enzyme treated low moisture content comestible products. US 5200215 by Nabisco.
Soerensen, J.F. and Sibbesen,O. (1999). Bacterial xylanase. UK A 9828599.2.
Claims (23)
1. A method of altering the sensitivity of a xylanase polypeptide to an inhibitor, which method comprises modifying one or more amino acid residues of said polypeptide; and measuring the sensitivity of said xylanase polypeptide to a xylanase inhibitor; such that the polypeptide or fragment thereof has altered sensitivity to a Xylanase inhibitor as compared with the parent xylanase enzyme, wherein said xylanase has at least one of said amino acids modifications at any one of position 11, 12, 13, 15, 17, 29, 31, 32, 34, 113, 114, 119, 120, 121, 122, 123, 124 or 175 of the B. subtilis amino acid sequence shown as SEQ. ID. No. 1, or at equivalent position(s) in other homologous xylanases, wherein at least one of said amino acids modifications is at least at position 11, 12 or 13 of the B. subtilis amino acid sequence shown as SEQ. ID. No. 1 or at equivalent position(s) in other homologous xylanases.
2. A method of altering the sensitivity of a xylanase polypeptide to an inhibitor, which method comprises modifying two or more amino acid residues of said polypeptide; and optionally, measuring the sensitivity of said xylanase polypeptide to a xylanase inhibitor; such that the polypeptide or fragment thereof has altered sensitivity to a xylanase inhibitor as compared with the parent xylanase enzyme, wherein said modifications are to two or more of positions 11, 12, 13, 15, 17, 29, 31, 32, 34, 113, 114, 119, 120, 121, 122, 123, 124 and 175 of the B. subtilis amino acid : sequence shown as SEQ. ID. No. 1, or at equivalent position(s) in other homologous xylanases, wherein one of said amino acid modifications is at position 11.
3. A method according to any one of the preceding claims wherein said amino acid modification is carried out by site-directed mutagenesis.
4. A method of altering the sensitivity of a xylanase polypeptide to an inhibitor, which method comprises modifying two or more amino acid residues of said polypeptide; and optionally, measuring the sensitivity of said xylanase polypeptide to a xylanase inhibitor; such that the polypeptide or fragment thereof has altered sensitivity to a xylanase inhibitor as compared with the parent xylanase enzyme, AMENDED SHEET wherein said modifications are to two or more of positions 11, 12, 13, 15, 17, 29, 31, 32,34, 113, 114, 119, 120, 121, 122, 123, 124 and 175 of the B. subtilis amino acid sequence shown as SEQ. ID. No. 1, or at equivalent position(s) in other homologous xylanases, wherein said amino acid modifications are carried out by site-directed mutagenesis, and wherein one of said amino acid modifications is at position 11, 12 or 13.
5. A method according to any preceding claim wherein one of said amino acids : modifications is any of: D11Y, DI1IN, D11F, D11K, D11S, D11W, G12F, G13F, [15K, N17K, N17Y, N17D, N29K, N29Y, N29D, S31K, S31Y, S31D, N32K, G34D, G34F, G34T, Y113A, Y113D, Y113K, N114A, N114D, N114F, N114K, D119K, D119Y, D119N, G120K, G120D, G120F, G120Y, G120N, D121IN, DI121K, DI2IF, D121A, R122D, R122F, R122A, T123K, T123Y, T123D, T124K, T124Y, T124D, Q175E, Q175S and Q175L.
6. A method according to any preceding claim wherein one of said amino acids : modifications is any of: D11Y, D1IN, D11F, D11K, D11S or D11W.
7. A method according to any preceding claim wherein one of said amino acids modifications is D11F.
8. A method according to any one of the preceding claims wherein two of said amino acid modifications are D11F and R122D.
9. A method according to any one of the preceding claims wherein said xylanase is a family 11 xylanase.
10. A variant polypeptide or fragment thereof having xylanase activity, comprising two or more amino acid modifications, wherein said amino acid modifications are at two or more of positions 11, 12, 13, 15, 17, 29, 31, 32, 34, 113, 114, 119, 120, 121, 122, 123, 124 and 175 of the B. subtilis amino acid sequence shown as SEQ. ID. No. 1, or at equivalent position(s) in other homologous xylanases, such that the polypeptide or fragment thereof has altered sensitivity as compared with the parent xylanase, wherein one of said amino acid modifications is at position 11 and wherein said amino acids modifications are any of: D11Y, DIIN, DI11F, D11K, D118, D11W, GI12F, G13F, 115K, N17K, N17Y, N17D, N29K, N29Y, N29D, S31K, S31Y, S31D, N32K, G34D, G34F, G34T, Y113A, Y113D, Y113K, N114A, N114D, N114F, N114K, D119K, D119Y, D119N, G120K, G120D, G120F, G120Y, G120N, DI12IN, D121K, DI121F, D121A, R122D, R122F, R122A, T123K, T123Y, T123D, T124K, T124Y, T124D, Q175E, Q175S and Q175L.
11. A variant polypeptide or fragment thereof having xylanase activity, comprising two or more amino acid modifications, wherein said amino acid modifications are at two or more of positions 11, 12, 13, 15, 17, 29, 31, 32, 34, 113, 114, 119, 120, 121, 122, 123, 124 and 175 of the B. subtilis amino acid sequence AMENDED SHEET shown as SEQ. ID. No. 1, or at equivalent position(s) in other homologous xylanases, such that the polypeptide or fragment thereof has altered sensitivity as compared with the parent xylanase, wherein said amino acid modifications are introduced by site- directed mutagenesis and wherein at least one of said amino acid modifications is at position 11, 12 or 13 and wherein said amino acids modifications are any of: D11Y, D1IN, D11F, D11K, D11S, D11W, G12F, G13F, 115K, N17K, N17Y, N17D, N29K, N29Y, N29D, S31K, S31Y, S31D, N32K, G34D, G34F, G34T, Y113A, Y113D, Y113K, N114A, N114D, N114F, N114K, D119K, D119Y, D119N, G120K, G120D, G120F, G120Y, G120N, DI12IN, DI121K, Di21F, D121A, R122D, R122F, R122A, T123K, T123Y, T123D, T124K, T124Y, T124D, Q175E, Q175S and Q175L.
12. A variant polypeptide according to any of claims 10 or 11 wherein one of said amino acids modifications is D11Y, D11IN, D11F, D11K, D11S or D11W.
13. A variant polypeptide according to any of claims 10 to 12 wherein one of said amino acids modifications is D11F.
14. A variant polypeptide according to any one of claims 10 to 13 wherein two of : said amino acid modifications are D11F and R122D.
15. A variant polypeptide according to any one of claims 10 to 14, wherein said inhibitor is an inhibitor found naturally in plant tissues.
16. A variant polypeptide according to any one of claims 10 to 15, wherein said sensitivity to an inhibitor is reduced.
17. A composition comprising a variant polypeptide according to any one of claims 10 to 16.
18. A method of degrading or modifying a plant cell wall which method comprises contacting said plant wall with a polypeptide according to any one of claims 10 to 16 or a composition according to claim 17.
19. A method of processing a plant material which method comprises contacting said plant wall with a polypeptide according to any one of claims 10 to 16 or a composition according to claim 17.
20. A nucleotide sequence encoding a variant polypeptide according to any one of claims 10 to 16.
21. A construct comprising the nucleotide sequence of claim 20.
22. Use of a variant polypeptide according to any one of claims 10 to 16 in a method of modifying plant materials.
23. Use of a variant polypeptide according to any one of claims 10 to 16 in one or more of: baking, processing cereals, starch production, in processing wood, enhancing the bleaching process of wood pulp. AMENDED SHEET
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0005585A GB0005585D0 (en) | 2000-03-08 | 2000-03-08 | Enzyme |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200205956B true ZA200205956B (en) | 2003-02-17 |
Family
ID=9887219
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200205956A ZA200205956B (en) | 2000-03-08 | 2002-07-25 | Xylanase variants having altered sensitivity to xylanase inhibitors. |
Country Status (3)
Country | Link |
---|---|
ES (1) | ES2354533T3 (en) |
GB (1) | GB0005585D0 (en) |
ZA (1) | ZA200205956B (en) |
-
2000
- 2000-03-08 GB GB0005585A patent/GB0005585D0/en not_active Ceased
-
2001
- 2001-03-08 ES ES01912068T patent/ES2354533T3/en not_active Expired - Lifetime
-
2002
- 2002-07-25 ZA ZA200205956A patent/ZA200205956B/en unknown
Also Published As
Publication number | Publication date |
---|---|
GB0005585D0 (en) | 2000-05-03 |
ES2354533T3 (en) | 2011-03-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7527957B2 (en) | Methods of altering the sensitivity of a xylanase to a xylanase inhibitor | |
EP2382309B1 (en) | Polypeptides with xylanase activity | |
EP2382310B1 (en) | Polypeptides with xylanase activity | |
NO330277B1 (en) | Talaromyces emersonii beta-glucanases and polynucleotide, vector, host cell, polypeptide preparation method, composition and feed comprising the polypeptide | |
WO2007146944A2 (en) | Catalytically inactive proteins and method for recovery of enzymes from plant-derived materials | |
WO2003020923A1 (en) | Xylanase variants | |
WO2010072226A1 (en) | Polypeptides with xylanase activity | |
Guo et al. | A family 30 glucurono-xylanase from Bacillus subtilis LC9: expression, characterization and its application in Chinese bread making | |
EP1184460A1 (en) | Modified fungal xylanases | |
ZA200205956B (en) | Xylanase variants having altered sensitivity to xylanase inhibitors. | |
Kalinina et al. | Expression of the Xylanase Gene from Paenibacillus brasilensis X1 in Pichia pastoris and Characteristics of the Recombinant Enzyme | |
AU2006203392A1 (en) | Xylanase variants having altered sensitivity to xylanase inhibitors |